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Blacks in the country suffer from higher prevalences of obesity, diabetes, 
hypertension and cardiovascular disease compared to whites. Paradoxically, they 
have the lowest prevalence of the Metabolic Syndrome (MS) compared to whites and 
Mexican Americans. This is likely due to the fact that blacks tend to have lower 
triglycerides (TG) and higher high density cholesterol (HDL) levels. We challenged 
the current lipid criteria established by the Adult Treatment Panel III for the detection 
of the MS and set out to find more appropriate TG and HDL cutoffs to detect the MS 
in blacks. Using data from the National Health and Nutrition Examination Survey 
from 1999-2006, we identified that a more appropriate TG cutoff for blacks to detect 
the MS is 110 mg/dL but were not able to identify more suitable HDL cutoffs. Our 
results confirm that race/ethnic-specific criteria should be established for the 
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Chapter 1: Introduction 
 
Cardiovascular Disease 
An estimated 80,000,000 American adults have one or more types of 
cardiovascular disease (CVD), the number one killer of men and women in the United 
States (U.S.). It refers to a class of diseases that involve the heart and/or blood vessels 
and includes any of the following systemic abnormalities: coronary heart disease, 
stroke, high blood pressure (BP), acute coronary syndrome (acute myocardial 
infarctions and unstable angina), angina pectoris, congenital cardiovascular defects, 
heart failure, and peripheral arterial disease
1
.  
According to the American Heart Association (AHA) one in three adults in 
the in the country has some form of CVD. Each day nearly 2,400 Americans die of 
CVD, at an average of one death every 36 seconds. CVD claims more lives yearly 





The Metabolic Syndrome 
 In 1988, Dr. Gerald M. Reaven revealed that insulin resistance and its related 
compensatory hyperinsulinemia were central to the etiology of type 2 diabetes, 
hypertension (HT), and CVD, particularly coronary artery disease. In his 
investigations Reaven identified the co-occurrence of several metabolic abnormalities 
such as resistance to insulin-stimulated glucose uptake, glucose intolerance, 




lipoprotein cholesterol (HDL), and elevated BP. At the time, he called this clustering 
of abnormalities „Syndrome X‟ due to the fact that it was largely not understood. 
Presently it is more commonly known as the Metabolic Syndrome (MS), but because 
more recent evidence points out that the underlying abnormality that leads to these 
changes is resistance to glucose-mediated disposal, it is not difficult to see why it has 
also been aptly termed the „Insulin Resistance Syndrome‟
3, 4
.  
In order to more effectively detect the presence of the MS, and in light of the 
fact that its prevalence has reached epidemic proportions worldwide, several major 
health organizations have proposed sets of defining criteria for the syndrome. These 
organizations include the National Heart, Lung, and Blood Institute (NHLBI) of the 
National Institutes of Health (NIH), the World Health Organization (WHO), the 
International Diabetes Federation (IDF), and the European Group for the Study of 
Insulin Resistance (EGIR). 
 Nationally, the Third Report of the National Cholesterol Education Program 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults, Adult Treatment Panel III (NCEP, ATP III), instituted by the NHLBI, defines 
the MS as having three or more of the following abnormalities: a waist circumference 
(WC) of 102 cm (40 inches) or greater in men and 88 cm (35 inches) or greater in 
women, a blood TG concentration of 150 mg/dL or higher, HDL cholesterol levels of 
less than 40 mg/dL in men and less than 50 mg/dL in women, a BP of 130/85 mm Hg 
or higher or drug treatment for HT, and fasting plasma glucose (FPG) level of 100 








In the U.S. an estimated 76 million people have the MS. The age-adjusted 
prevalence among adults is 34 percent, with men having slightly higher prevalence 
(35.1%) than women (32.6%)
6
. According to the AHA Heart Disease and Stroke 
Statistics 2008 report, Mexican Americans (MA) have the highest age-adjusted 
prevalence of the MS in the country with 31.9 percent of MA‟s suffering from the 
syndrome. Whites follow MA‟s with a prevalence of 23.8 percent. Blacks have the 
second to lowest MS prevalence of 21.6 percent. People reporting “other” race or 
ethnicities have the lowest prevalence at 20.3 percent
2
. 
As we can see, statistics show that the prevalence of the MS is lower overall 
among black men and women as compared to other racial and ethnic groups. 
However, this seems paradoxical due to the fact that blacks have one of the highest 
CVD rates both nationally and worldwide
7-9
. What is more, blacks have higher rates 
of overall obesity and central obesity, diabetes, hyperglycemia, HT, and insulin 
resistance as compared to whites. They also tend to have higher CVD mortality, even 
in the absence of diabetes, than whites 
8, 10
. 
It has been observed that for genetic and anatomical reasons blacks have 
lower plasma TG levels and higher HDL levels, even in the presence of diabetes and 
insulin resistance, and at similar levels of obesity as whites. Because of these 
differences in lipid and lipoprotein concentrations many blacks do not meet the 
criteria the MS proposes. In light of this, several research groups question the utility 




race/ethnic-specific definitions be designed and instituted. Some attempts have been 
made to find more suitable lipid and lipoprotein cutoffs among this population, but 
unfortunately such studies have been conducted in small samples not representative 




Purpose of the Study 
The purpose of this study was to help reveal that lipid and lipoprotein 
parameter distributions are different across racial/ethnic groups and that using single 
TG and HDL cutoffs for detecting the presence of the MS is not equally helpful 
across all racial/ethnic groups. With this in mind, we set out to find more suitable TG 
and HDL cutoffs for blacks to adequately predict the MS utilizing a sample 
representative of the current U.S. population. We also sought to add support to the 
idea that the currently established lipid and lipoprotein parameter cutoffs might not be 
sufficient to predict diabetes and CVD risk among all racial/ethnic populations, 
particularly blacks.  
 
Research Hypothesis 
 We hypothesized that a TG cutoff point that is lower than the currently 
established 150 mg/dL by NCEP‟s ATP III criteria would be a more precise and 
accurate predictor of the MS in blacks. Also, we expected that cutoffs for HDL levels 
greater than 40 mg/dL for men and 50 mg/dL for women would be necessary to stave 






Chapter 2: Research Objectives 
 
This study was designed to answer the following questions: 
 
 
1. What is the prevalence of MS and CVD among non-Hispanic whites (NHW), 
non-Hispanic blacks (NHB) and Mexican Americans (MA) in NHANES 1999 to 
2006, a nationally representative sample of the U.S. population? How are these 
prevalences different between males and females and between racial/ethnic 
groups? 
 
2. What is the prevalence of MS and CVD risk factors: overweight and obese body 
mass index (BMI), elevated WC, elevated total cholesterol, elevated LDL, low 
HDL, elevated TG, elevated FPG, HT, and diabetes among NHW‟s, NHB‟s and 
MA‟ in NHANES 1999 to 2006? How are these prevalences different between 
racial/ethnic groups? 
 
3. What is the relationship between the predictor variables of interest, TG and HDL, 
and MS while controlling for age, race/ethnicity, BMI, WC, LDL cholesterol, 
blood glucose, systolic BP, diastolic BP, socioeconomic (education, income, 
health insurance coverage) and lifestyle factors (physical activity, smoking, 






4. Are the currently proposed cutoffs for TG and HDL accurate and precise 
predictors of MS for non-Hispanic blacks? If not, what are more accurate and 
precise cutoffs? 
 




Chapter 3: Literature Review 
 
Cardiovascular Disease 
CVD is the number one killer of men and women in the U.S. It refers to a 
class of diseases that involve the heart and blood vessels and includes any of the 
following systemic abnormalities: coronary heart disease (CHD), stroke 
(cerebrovascular disease), high BP or HT, acute coronary syndrome (acute 
myocardial infarctions and unstable angina), heart failure, and peripheral arterial 
disease. CHD is comprised of acute MI, other acute ischemic (coronary) heart 





Cardiovascular Disease Mortality Statistics 
Each day nearly 2,300 Americans die of CVD, at an average of one death 
every 38 seconds. On every year since 1900 except 1918, CVD has accounted for 
more deaths than any other major cause of death in the country. Yearly, CVD claims 
more lives than cancer, chronic lower respiratory diseases (CLRD), and accidents 
combined. The Centers for Disease Control and Prevention (CDC), National Center 
for Health Statistics (NCHS) 2006 mortality data show that CVD was the underlying 
cause of death in one out of every 2.9 deaths in the country. The 2006 overall death 
rate due to CVD was 262.5 (per every 100,000). Death rates by race and gender were: 
306.6 for white males, 422.8 for black males, 215.5 for white females, and 298.2 for 




and older were diseases of the heart, cancer, stroke, and CLRD, in decreasing order. 
In older men, the leading causes were diseases of the heart, cancer, CLRD, and 
stroke, also in decreasing order. Interestingly, the actual number of deaths due to 
CVD declined 12.9 percent per year from 1996 to 2006, leading to a total CVD death 
rate decline of 29.2 percent (Figure 1)
6
. Reductions in serum cholesterol, BP, and 






Figure 1. Deaths due to CVD (United States: 1900–2006). CVD does not include 
congenital CVD. Source: Lloyd-Jones et al., 20106 
 
Cardiovascular Disease Morbidity Statistics 
In spite of the declining CVD death rate, “the burden of disease remains 
high”, according to the AHA‟s 2010 Heart Disease and Stroke Statistics. This is 
shown in that one in three or about 81.1 million adults in the country has one or more 
types of CVD. According to the CDC‟s, National Health Interview Survey (2008), the 




that 12.1 percent have heart disease, 6.5 percent have CHD, 23.3 percent have HT, 
and 2.7 percent have had a stroke. Among blacks, 10.2 percent have heart disease, 5.6 
percent have CHD, 31.8 percent have HT, and 3.6 percent have had a stroke. Among 
Hispanics or Latinos, 8.1 percent have heart disease, 5.7 percent have CHD, 21.0 




Cardiovascular Disease Incidence Statistics 
Based on data from NHLBI‟s Framingham Heart Study (FHS), average 
annual rates of first CVD events rise from three per 1,000 men at ages 35 to 44 to 74 
per 1,000 men at ages 85 to 94. Comparable rates occur 10 years later among women, 
with the gap narrowing with advancing age (Figure 2). Before 75 years of age, a 
higher proportion of CVD events due to CHD occur in men than in women, and a 
higher proportion of events due to stroke occur in women than in men. The lifetime 
risk for all CVD in recipients free of disease at 40 years of age is two in three for men 
and more than one in two for women. Analysis of FHS data among participants free 
of CVD at 50 years of age demonstrated that the lifetime risk for developing CVD is 
51.7 percent for men and 39.2 percent for women. Median overall survival is 30 years 









Figure 2. Prevalence of CVD among adults ≥ 20 years of age by age and sex 
(NHANES: 2003–2006). These data include CHD, HF, stroke, and HT. Source: Lloyd-




Coronary Heart Disease: the Deadliest Cardiovascular Disease  
As shown in figure 3, CHD leads to the highest number of deaths among all 
cardiovascular diseases. In 2006, this disease alone caused one out of six deaths in the 
U.S. An estimated 17,600,000 Americans 20 years of age and older have CHD based 
on NHANES 2003-2006 estimates. Total CHD prevalence is 7.9 percent in U.S. 
adults 20 years of age and older. CHD prevalence is 9.1 percent for men and 7.0 
percent for women. Among NHW‟s, CHD prevalence is 9.4 percent for men and 6.9 
percent for women. Among NHB‟s, CHD prevalence is 7.8 percent for men and 8.8 
percent for women. MA‟s have the lowest prevalence of the disease with 5.3 percent 






Figure 3. Percentage breakdown of deaths due to CVD (United States: 2006). *Not a 





Detection of Cardiovascular Disease 
In 2001 the NHLBI of the NIH redefined the Third Report of the National 
Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults III (ATP III; Table 1). According to 
this new ATP III revision elevated blood levels of LDL cholesterol (≥ 160mg/dL) is 
the major risk factor for CHD. In keeping with this ATP III revision, goals for LDL 
cholesterol may be modified according to other concomitant risk factors. These other 
risk factors are: cigarette smoking, HT, low HDL cholesterol (< 40 mg/dL), family 
history of premature CHD (CHD in male first degree relative < 55 years; CHD in 













Table 1. ATP III classification of LDL, total, and HDL cholesterol (mg/dL) 
 
 
LDL Cholesterol – Primary Target of Therapy 
< 100   Optimal 
100-129 Near optimal/above optimal 
130-159 Borderline High 
160-189 High 
≥ 190   Very High 
 
Total Cholesterol 
< 200   Desirable 
200-239 Borderline high 
≥ 240   High 
 
HDL Cholesterol 
< 40   Low 
≥ 60   High 
 






Table 2. Major risk factors (exclusive of LDL) that modify LDL goals 
 
 Cigarette smoking 
 Hypertension (Blood pressure ≥ 140/90 mmHg or on antihypertensive 
medication) 
 Low HDL cholesterol (< 40 mg/dL)* 
 Family history of premature CHD (CHD in male first degree relative < 55 
years); CHD in female first degree < 65 years) 
 Age (men ≥ 45; women ≥ 55 years) 
 
 
* HDL cholesterol ≥ 60 mg/dL counts as a “negative” risk factor; its presence 
removes one factor from total count. 




The Metabolic Syndrome and its Definitions 
 The AHA and the NHLBI describe the MS, also known as „Syndrome X‟, the 




Syndrome‟, as “a group of multiple, interrelated risk factors of metabolic origin that 
appear to promote the development of atherosclerotic cardiovascular disease 
(ASCVD) and type 2 diabetes mellitus (or its risk)”
5, 14
. According to a statement 
from the IDF, “the MS is a cluster of the most dangerous heart attack risk factors: 
diabetes and prediabetes, abdominal obesity, high cholesterol and high BP”
7
. People 
with the MS are three times as likely to have a heart attack or stroke compared with 
people without the syndrome and twice as likely to die from these. People with MS 
also have a five-fold greater risk of developing type 2 diabetes
7, 15
. Furthermore, CVD 
and type 2 diabetes are not the only clinical syndromes associated with the MS, HT, 
polycystic ovarian syndrome, non-alcoholic liver disease, sleep disordered breathing, 
fatty liver, cholesterol gallstones, gout, depression, musculoskeletal disease, and 
certain types of cancer have also been found to be associated with the disorder
4, 15, 16
. 
 The MS appears to promote the development of ASCVD at various levels
17, 18
. 
Elevations of apolipoprotein B (apo B) containing lipoproteins initiate atherogenesis 
and start lesion development. This plaque development is accelerated by low 
circulating levels of HDL and elevated BP, by inflammatory cytokines, among these 
interleukin 6, tumor necrosis factor alpha, and CRP, and by elevated plasma glucose. 
Advanced plaques become unstable and they begin to rupture. When ruptures occur, a 




Like for CHD risk, ATP III has proposed a set of diagnostic criteria for the 
diagnosis of the MS (Table 3). According this criteria the presence of three out of five 




88 cm in women), elevated TG (≥ 150 mg/dL, or drug treatment for elevated TG), 
reduced HDL (< 40 mg/dL in men, < 50 mg/dL in women, or drug treatment for 
reduced HDL), elevated BP (≥ 130 mm Hg systolic BP or ≥ 85 mm Hg diastolic BP, 
or drug treatment for elevated BP), and/or elevated FPG (≥ 100 mg/dL, or treatment 
for elevated glucose)
5
. These conditions, when clustered, not only indicate a diagnosis 
for the MS, but also help identify patients at risk for advanced CVD and offer an 




Table 3. NCEP’s ATP III diagnostic criteria for the Metabolic Syndrome 
 
 
According to the ATP III definition, for a person to be defined as having the 
MS they must have three out of the five following: 
 
Indicator     Level indicative of MS 
Elevated waist circumference  ≥ 102 cm (≥ 40 in.) in men 
      ≥ 88 cm (≥ 35 in.) in women 
 
Elevated triglycerides   ≥ 150 mg/dL  
or drug treatment for elevated 
triglycerides 
 
Reduced HDL cholesterol   < 40 mg/dL in men 
      < 50 mg/dL in women 
      or drug treatment for low HDL 
       
Elevated blood pressure   ≥ 130 mmHg systolic blood pressure 
      or ≥ 85 mmHg diastolic blood pressure 
or drug treatment for elevated blood 
pressure 
      
Elevated fasting glucose ≥ 100 mg/dL or drug treatment for 
elevated fasting glucose 
 







It is important to note that in the 2001 ATP III definition of the MS, threshold 
level of FPG was set at 110 mg/dL. In 2004 this cutoff was modified to be 100 
mg/dL, in accordance with the American Diabetes Association‟s update of the 
definition of impaired fasting glucose
5, 20, 21
. 
Among the key underlying factors for the MS are abdominal obesity and 
insulin resistance, but other associated conditions include physical inactivity, aging, 
hormonal imbalances, and genetic predisposition
22
. Prospective population studies 
have shown that the MS significantly increases long-term risk ASCVD events and 
diabetes, nonetheless additional research is required to better understand the 
pathophysiology of the MS
5
. It is known that the concurrent presence of the metabolic 
abnormalities observed in individuals with the MS confer a substantial cardiovascular 
risk over and above the sum of the risk of each abnormality
7
. When clustered, these 
abnormalities not only indicate a diagnosis but more importantly help identify 
patients at risk for accelerated CVD
19
. 
The clustering of risk factors that characterize the MS is now considered to be 
the driving force for a worldwide CVD epidemic
7
. In light of this, the IDF has 
established a definition for the MS to be used worldwide in clinical practice (Table 
4). This definition classifies a person as having the MS if they have central obesity 
defined as a WC of 94 cm or greater for Europid men and 80 cm or greater for 
Europid women, as well as two of the following four factors: elevated TG levels (≥ 
150 mg/dL) or treatment for elevated TG, reduced HDL (< 40 mg/dL in males and < 




diastolic BP ≥ 85 mm Hg) or treatment for elevated BP, elevated FPG (≥ 100 mg/dL) 





Table 4. The International Diabetes Federation definition of the Metabolic 
Syndrome   
 
 
According to the new IDF definition, for a person to be defined as having the 
MS they must have: 
 
Central obesity (defined as a waist circumference ≥ 94 cm for Europid men 
and ≥ 80 cm for Europid women, with ethnic specific values for other ethnic groups) 
plus any two of the following four factors: 
 
 Raised TG level: ≥ 150 mg/dL, or specific treatment for this lipid 
abnormality 
 
 Reduced HDL cholesterol: < 40 mg/dL in males and < 50 mg/dL in 
females, or specific treatment for this lipid abnormality  
 
 Raised blood pressure: systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg, or 
treatment of previously diagnosed HT 
 
 Raised fasting plasma glucose ≥ 100 mg/dL, or previously diagnosed type 
2 diabetes 
[If > 100 mg/dL, an oral glucose tolerance test is strongly 
recommended but is not necessary to define presence of the syndrome] 
 






In order to make this MS definition applicable worldwide, the IDF has also 
specified different WC cutoffs for central obesity which are specific to gender and 
ethnic group (not country of residence). These include: Europids, South Asians, 
Chinese, Japanese, Ethnic South and Central Americans, Sub-Saharan Africans, and 







Table 5. The International Diabetes Federation Metabolic Syndrome definition - 
ethnic specific values for waist circumference 
 
 
Country/ Ethnic group 
 
Waist circumference† 









































≥ 90 cm 
 
Ethnic South and Central 
Americans 
 
Use South Asian recommendations until more specific 
data are available 
 
Sub- Saharan Africans 
 
Use European data until more specific data are available 
East Mediterranean and 
Middle East (Arab) 
populations 
 
Use European data until more specific data are available 
 
* In the USA, the ATP III values (102 cm male; 88 cm female) are likely to continue to be used for 
clinical purposes 
** Based on a Chinese, Malay and Asian Indian population 
*** Subsequent data analyses suggest that Asian values (male, 90cm; female 80cm) should be used for 
Japanese populations until more data are available. 
†In future epidemiological studies of populations of Europid origin, prevalence should be given using 
both European and North American cut-points to allow better comparisons. 
 
Although a higher cut-point is currently used for all ethnic groups in the USA for clinical diagnosis, it 
is strongly recommended that for epidemiological studies and, wherever possible, for case detection, 
ethnic group specific cut-points should be used for people of the same ethnic group wherever they are 
found. Thus the criteria recommended for Japan would also be used in expatriate Japanese 
communities, as would those for South Asian males and females regardless of place and country of 
residence.  








In addition, the WHO also has proposed working criteria for the MS similar to 
that constructed by ATP III. These criteria are similar in that they focus on obesity, 
dyslipidemia, hyperglycemia, and HT but differ in their specific constituents used to 




Table 6. The World Health Organization’s definition of the Metabolic  
   Syndrome 
 
 
Subjects are identified as having the MS if they have hyperinsulinemia (defined as the 
upper quartile of the non-diabetic population), a 2-hour glucose ≥ 140 mg/dL, a fasting plasma 
glucose ≥ 110 mg/dL, or taking medication for diabetes and have two or more of the following 
metabolic abnormalities:  
 
 Waist-to-hip ratio > 0.90 in men and > 0.85 in women or a BMI ≥ 30 kg/m2 
 
 TG levels ≥ 1.7 mmol/L (150 mg/dL) or ASCVD HDL < 0.9 mmol/L (35 mg/dL) in men 
and < 1.0 mmol/L (39 mg/dL) in women 
 
 Blood pressure ≥ 140/90 mm Hg (or treated HT) 
 
 Microalbuminuria (urinary albumin excretion rate ≥ 20 μg/min or albumin:creatinine 
ratio ≥ 30 mg/g) 
 
 
Sources: Meigs et al., 2003
24




In 1999, after the WHO established its definition of the MS, the EGIR also 
constructed its own. This definition would be more useful in epidemiological trials 
but it can only be applied to non-diabetic individuals. Table 7 presents the criteria 









Table 7. The European Group for the Study of Insulin Resistance’s definition of  
   the Metabolic Syndrome 
 
 






Metabolic Syndrome Statistics 
One quarter of the world‟s adult population has the MS
7
. In 2007 the AHA 
estimated that an estimated 76 million U.S. residents 20 years and older had the MS
1
. 
This is in sharp contrast with the 47 million residents that had the MS as of 1994
2
. 
The age-adjusted prevalence of MS in the nation according to NHANES 2003-2006 is 
approximately 34 percent. The age-adjusted prevalence is 35.1 percent for men and 
32.6 percent for women. Age-adjusted prevalences of men with MS by race and 
ethnicity are 37.2 percent for NHW, 25.3 percent for NHB, and 33.2 percent for MA 
men. Among women, the percentages are 31.5 percent for NHW, 38.8 percent for 





Insulin resistance (defined as hyperinsulinemia - top 25% of fasting insulin values among the 
non-diabetic population) 
 
Plus two of the following: 
 
Fasting plasma glucose: ≥ 6.1 mmol/L (110 mg/dL) but non-diabetic 
Blood pressure: ≥ 140/90 mmHg or treatment 




HDL cholesterol: < 1.0 mmol/L (39 mg/dL) or treatment 
Obesity as defined by waist circumference: 
Men: ≥ 94 cm 





Racial and Ethnic Differences in Prevalence of the Metabolic Syndrome 
As we have observed the prevalence of the MS is lower overall among blacks 
compared to other racial and ethnic groups. However, this seems paradoxical due to 
the fact that blacks have one of the highest CVD rates not only in the country, but in 
the world
7, 27
. In blacks HT occurs 50 percent more frequently, is seen earlier, is more 
severe, and is often associated with target organ damage, left ventricular hypertrophy, 
heart failure, end-stage renal disease, fatal and nonfatal stroke, and CHD-related 
mortality
19
. Besides having a greater prevalence of HT, blacks have higher rates of 
overall obesity, central obesity, and diabetes, hyperglycemia, and insulin resistance as 
compared to whites. They also tend to have higher CVD morbidity and mortality, 




Lipid and Lipoprotein Differences between Racial/Ethnic Groups 
One of the proposed reasons for this ambiguity is that blacks tend to have 
what appears to be a more favorable lipid profile and so do not as easily meet the 
criteria the MS proposes
29, 30
. The tendency is for blacks to have lower TG levels and 
higher HDL cholesterol levels even in the presence of higher insulin levels, diabetes, 
and obesity than their white and MA counterparts
31, 32
. In light of this, several 
research groups question the utility of the present MS criteria across different groups 
and suggest that criteria specific to race or ethnic group should be utilized to diagnose 
the MS
8, 10, 19, 31, 33, 34
. 
In a study 29 white American and 22 African American women, MacLean and 




prevalence of CVD even without having the alterations in lipid concentrations 
observed among their obese, diabetic white American counterparts. The white 
diabetic women in this study exhibited more atherogenic lipid concentrations 
compared to lean and obese white women without diabetes, as is generally expected. 
Interestingly, the lipid concentrations of the diabetic African American women were 
relatively similar to those found among the non-diabetic, lean and obese African 
American women. What is more, the black American women cohort demonstrated 
higher HDL and lower TG and LDL concentrations, regardless of level of obesity or 
presence of diabetes compared to the white American women. Nevertheless, the 
investigators note that although the increased CVD rate among obese, diabetic white 
subjects can be partly attributed to increased lipid concentrations, elevated CVD 
incidence persists among obese, diabetic African American subjects in spite of the 
absence of the expected increases in lipid concentrations. In other words, the 




On a related note, MacLean and colleagues add that in the presence of 
diabetes and obesity, subtle racial differences may exist not only in terms of lipid 
concentrations, but also in lipid particle size and in lipoprotein subpopulation 
distributions. According to the researchers, in African Americans lipoprotein 
subpopulation distributions may be more predictive of vascular disease than lipid 
concentrations alone. In view of this and of the racial differences in lipoprotein 




suggesting that race-specific criteria are needed in clinical settings to better identify 
patients at high risk for CVD
31
. 
A similar argument was presented by Ferdinand and Clark in their 2004 
review of MS among African Americans. In it the authors draw attention to the fact 
that among African American men there appears to be an unexpected lower rate of 
MS as compared to white and MA men, which they argue is specifically caused by an 
underestimation of the presence of the MS. This underestimation is due in turn to 
higher HDL cholesterol and to lower TG and LDL cholesterol levels observed among 
this group. Like MacLean et al., the study group adds that the presence of these 
apparently more favorable lipoprotein levels does not appear to be protective against 
the negative effects of CHD and that in fact, CHD-related death rates within this 
population remain not only the highest in the country, but also in the world
19
. 
More recently, Sumner, in his 2009 review of racial and ethnic lipid and 
lipoprotein differences, argued that even though the cause of lower TG and higher 
HDL levels in blacks is largely unknown, the relative absence of dyslipidemia of 
insulin resistance in blacks may explain their lower-than-expected prevalence of the 
MS. The author claims that “it is also possible that the adult thresholds used to define 
hypertriglyceridemia (≥ 150 mg/dL) and low HDL (< 40 mg/dL in men, < 50 mg/dL 
in women) are not set at the appropriate level to identify high risk for diabetes and 
CVD risk in blacks.” In view of this, the author concludes that ethnic-specific 
guidelines for lipids may be necessary. He adds that alternatively, blacks with the MS 
may transition so quickly from having the MS into CVD and diabetes that cross-






Meanwhile, Gaillard and colleagues, in their review of MS definitions and 
classifications, challenge the current established definitions for the MS and suggest 
that the current ATP III, WHO, and IDF definitions of the MS should be redefined 
among different racial and ethnic populations, particularly in blacks. They surmise 
that based on the higher CVD outcomes in blacks despite of their lower rates of MS, 
there are racial/ethnic differences in the impact of the five components of MS for 
detecting future CVD and type 2 diabetes. Therefore, the relationships between 
several components of the MS and of insulin resistance are well established in whites 
but these relationships remain controversial in blacks
8
.  
Among blacks themselves, it has been argued that because there is limited 
data from studies based on sub-Saharan Africans, it is difficult to make 
recommendations in terms of components of the MS that are generalizable for all 
black populations. Preliminary studies nonetheless have shown that Ghanians and 
South African blacks both are more insulin resistant than whites. Lower prevalences 
of the MS have been reported in Cameroonians who live in rural areas versus urban 
areas. Also, the metabolic components of the MS in Ghanians, such as BP and lipids 
and lipoproteins have been observed to be comparable to those of African Americans, 
South Africans, and Afro-Caribbeans. According to Gaillard and colleagues, these 
studies collectively confirm that people of the African Diaspora are similar in this 









Racial and Ethnic Differences in Visceral Adiposity 
As previously mentioned, blacks have higher rates of overall obesity and 
central obesity as compared to whites and MA‟s. According to Gaillard et al., “the 
distribution of excess adipose mass in adults may be more important than total fat in 
conferring metabolic and cardiovascular risk
8
.” Excess fat in the upper body region, 
particularly abdominal or visceral adipose tissue, is linked with a more atherogenic 
plasma lipid profile and greater insulin resistance. Abdominal obesity has been shown 
to be associated with the MS, particularly among individuals with higher amounts of 
visceral adipose tissue
36
. In fact, central obesity, measured by WC, is one of ATP 
III‟s criteria for the MS
8
. Racial differences nonetheless have been reported in the 
relationship of body fatness to visceral adipose tissue accumulation, with whites 




Studies performed in white populations have shown that excess visceral 
adipose tissue accumulation in obese subjects is related to reduced plasma HDL 
levels
39
. As mentioned before, whites tend to have higher visceral adipose tissue 
compared to blacks, even when they have comparable BMI‟s and WC, and in spite of 
the fact that black women have greater total fat. It is probable that one reason why 
more favorable TG and HDL cholesterol levels are so often observed among blacks is 
precisely their lower visceral tissue accumulation








The Role of Lipases  
Previous studies have shown that the TG lipases, lipoprotein lipase (LPL) and 
hepatic lipase (HL), are important correlates of plasma HDL cholesterol levels. LPL, 
found in the capillary endothelial cells in muscle and adipose tissue, is the enzyme 
responsible for clearing TG-containing lipoproteins from circulation. A deficiency of 
LPL leads to hypertriglyceridemia. Insulin leads to the synthesis of LPL and to its 
placement on the capillaries. Over time it has been repeatedly shown that subjects 
with high plasma LPL activity have increased HDL and decreased TG levels. 
Conversely, HL is expressed in the liver and the adrenal glands and its primary 
function is to convert intermediate density lipoproteins to LDL. Unlike LPL, HL is 
inversely correlated to plasma HDL levels, leading to decreased HDL levels in 
subjects with high HL activity
41
. 
The association between abdominal obesity and TG and HDL cholesterol was 
observed in a study of 723 subjects (32% black) using data from the Health, Risk 
Factors, Exercise Training, and Genetics (HERITAGE) Family Study
37
. The authors 
set out to test the hypothesis that lower accumulation of visceral adipose tissue could 
be responsible for the higher plasma HDL cholesterol levels in blacks those in whites. 
What they observed was that visceral adipose tissue accumulation, measured by 
computer tomography, showed a stronger correlation than total fat mass to TG, apo B, 
and total cholesterol to HDL ratio, as well as a negative correlation with HDL. White 
men had higher visceral adipose tissue deposition than black men, regardless of the 
fact that both groups had similar BMI and total body fat mass. Among women, both 




adiposity of black women, which in turn suggested that white women were more 
prone to visceral adipose tissue deposition than black women. White men showed 
increased TG and apoB concentrations and a higher ratio of total cholesterol to HDL 
cholesterol. White women had higher cholesterol, TG, and apoB levels. It is 
important to note that both white men and women showed lower LPL and higher HL 
activity than black men and women. These results illustrate that the generally more 
cardioprotective plasma lipoprotein profile found in abdominally obese black versus 
white individuals are explained to an extent, by a lower visceral adipose tissue 
deposition and a higher plasma LPL activity in blacks
37
. 
Previous studies have attributed the antiatherogenic properties of HDL to the 
reverse cholesterol transport mechanism. Furthermore, HDL has been suggested in 
recent studies to play an important role in the prevention of oxidative modification of 
LDL, which in turn contributes to the pathogenesis of atherosclerosis. Still, in spite of 
the seemingly protective HDL levels in blacks, still it is not known if HDL levels are 
truly cardioprotective in this racial group. If HDL levels are not cardioprotective, it is 
likely that other factors mitigate the potential cardiovascular beneficial effects of 
HDL in blacks. This is an issue remains to be investigated within this population. 
Gaillard et al. argue that in order to achieve the presumed antiatherogenic effects of 










Racial and Ethnic Differences in Insulin Resistance  
It is widely known that insulin resistance is often characterized by elevated 
TG levels. However, studies elucidating this relationship have mostly been performed 
in primarily white populations, meaning that in blacks the relationship between 
insulin resistance and TG has not been well established. In blacks lower levels of TG 
levels are observed even when they have more insulin resistance, which in turn is 
caused by decreased hepatic insulin extraction in this racial group. Although the 
reasons for these racial differences are not clear, it has been suggested that the higher 
activity of LPL may in part be the reason for this lack of association in blacks
37, 42
. 
What is more, in addition to having relatively lower serum TG, blacks have larger 




The mechanism whereby insulin resistance increases TG levels is by 
increasing hepatic TG production and secretion of very low density lipoproteins 
(VLDL) and by decreasing clearance of VLDL‟S and chylomicrons, both TG-rich 
lipoproteins, from circulation
43
. Previous studies have suggested that insulin 
resistance leads to an impairment in LPL activity
42
. However, studies elucidating this 
mechanism of action of insulin resistance and TG have been primarily performed in 
whites. More recent studies including blacks have shown that such a relationship is 
not as apparent in this racial group. In one such study of 107 non-diabetic African 
Americans enrolled in the Triglyceride and Cardiovascular Risk in African 
Americans (TARA) of the NIH, Sumner and colleagues observed precisely this. The 




significantly inversely correlated. However, in African American women this 
correlation was not significant. For men, TG was significantly higher among 
individuals with higher insulin resistance, but for women, TG did not change 
according to changes in insulin resistance. When the interaction between sex and 
insulin sensitivity was considered, the effect of insulin resistance was significant with 
TG rising as insulin resistance increased in men but not in women. In contrast, 
visceral adipose tissue was associated with a rise in TG levels in both men and 
women. What is more, visceral adipose tissue had an even greater impact on women 
than on men. The study group also measured gender differences in LPL activity 
where they observed no significant differences among the groups. For both men and 
women, TG levels were inversely correlated with LPL significantly. Based on these 
analyses, the authors affirmed that LPL activity appears to be a major determinant of 
TG levels. Of great importance was the fact that LPL activity did not change by tertile 
of insulin resistance both for the whole population, as well as when men and women 
were analyzed separately. In multiple regression analyses with LPL as the dependent 
variable and insulin sensitivity, BMI, and sex as independent variables, the 
contribution of insulin resistance was not significant. Their data suggest that LPL 
activity is independent of insulin status in this racial group. In light of this, Sumner 
and colleagues concluded that “the relationship between LPL activity and insulin 
resistance in African Americans is different from that observed in Caucasians and 
MA‟s.” All in all, in whites insulin resistance leads to impairment of LPL and 
subsequent elevated TG levels, but in blacks TG is cleared from circulation even in 






Why insulin resistance does not appear to adversely affect the lipid profile in 
blacks is still unknown and currently under investigation. According to Sumner 
differences in diet do not account for the lower TG and higher HDL levels observed 
in this racial group. What is known is that, as mentioned before, in blacks, LPL levels 
are higher and HL levels are lower, and insulin resistance does not appear to impair 
LPL activity. Such factors lead to unimpaired clearing of TG‟s from circulation even 
in the presence of insulin resistance in this population
10
. Moreover, it has been 
reported that blacks residing in diverse geographic locations have lower visceral 
adiposity despite increased insulin resistance when compared to whites. This has been 
confirmed in urban black South African when compared to white South Africans. The 
reason for this remains paradoxical. Thus, there is also a disassociation between 
insulin resistance and body fat distribution and composition in blacks, which is 




Attempts to Find More Suitable Lipid and Lipoprotein Thresholds  
These racial and ethnic differences in circulating TG and HDL concentrations 
warrant the need to revise the current cutoffs used to classify people as dyslipidemic. 
This is seen in that the use of one TG value in particular might be leading to the 
underestimation of the prevalence of the MS in blacks as compared to whites and 
MA‟s
44
. According to Sumner et al., “the consequence of under diagnosing insulin 
resistance and MS in blacks is that the opportunity for intervention to prevent CVD 
and diabetes in this group could be lost”
11
. Without understanding the relationship 




low-normal or normal TG levels in African Americans and underdiagnose the 
presence of CVD and related diseases
11, 42
. 
 In order to ameliorate the failure of the MS to detect insulin resistance in the 
black population, McLaughlin and colleagues set out to determine the lipid criteria 
that were most sensitive markers of insulin resistance. The study group observed that 
the cutoffs that were more predictive of insulin resistance were TG levels of 130 
mg/dL or greater and TG to HDL ratio values of 3.0 or greater. It is important to note 
though that this study was carried out in a primarily white population. The study 
sample consisted of healthy volunteers classified as overweight or obese which were 
87 percent white, nine percent Asian American, three percent Hispanic, and one 
percent black. The authors concluded that different markers or different cutoffs might 




 A couple of years later, Sumner et al. also set out to determine whether TG 
levels or the TG to HDL ratio adequately predicted insulin resistance in overweight 
and obese African Americans. Using a sample of 125 African Americans from the 
TARA study, the study group observed that fasting insulin level, BMI, and WC 
increased across tertiles of insulin resistance but that TG and the TG to HDL ratio did 
not. However, as in McLaughlin‟s study, this investigation included a small sample 
size. It also included a relatively young population of 20 to 50 years old. Still, the 
researchers concluded that using lipid criteria, specifically TG or the TG to HDL ratio 
in African Americans to diagnose insulin resistance, will lead to an underestimation 




using these markers of insulin resistance in African Americans they urge testing these 
criteria in a large population of African Americans over a wide age range
11
.  
All the above-mentioned observations provide evidence that the criteria for 
predicting vascular diseases may need to be race/ethnic-specific. Given the 
prevalence of obesity and diabetes in blacks and the substantial health care costs that 
are involved in treating vascular disease in these patients, studies designed to clarify 
the relationship between lipoprotein subpopulation distribution and vascular disease 






Chapter 4: Methods 
 
Survey Data 
The data used for this study was obtained from the 1999-2006 National Health 
and Nutrition Examination Survey (NHANES). All datasets as well as the pertaining 
documentation are accessible to the general public at http://www.cdc.gov/nchs 
/nhanes.htm. Four survey cycles in NHANES were combined together to increase the 
survey sample size and produce estimates with greater statistical reliability.  
The NHANES is a group of studies designed to assess the health and 
nutritional status of adults and children in the U.S. The survey combines interviews 
and physical examinations. NHANES is a major program of the NCHS, CDC and has 
the responsibility for producing vital and health statistics for the country. The 
NHANES began in the early 1960‟s when it was conducted as a series of separate 
surveys until 1999 when the survey became continuous. Since then the datasets are 
released in two year increments. The survey examines a nationally representative 
sample of about 5,000 persons yearly. These persons are located in counties across 
the country, 15 of which are visited each year. The NHANES interview includes 
demographic, socioeconomic, dietary, and health-related questions. The examination 
component consists of medical, dental, and physiological measurements, as well as 
laboratory tests administered by highly trained medical personnel
46
. 
NHANES data are not obtained using a simple random sample. Rather, a 
complex, multistage, probability sampling design is used to select participants 




not include persons residing in nursing homes, members of the armed forces, 
institutionalized persons, or U.S. nationals living abroad. The sampling procedure for 
NHANES consists of four stages. In stage one, primary sampling units (PSU‟s) are 
selected. These are mostly single counties or, in some cases, groups of contiguous 
counties with probability proportional to a measure of size (PPS). In the second stage, 
the PSU‟s are divided up into segments (generally city blocks or their equivalent). As 
with each PSU, sample segments are selected with PPS. In the third stage, households 
within each segment are listed, and a sample is randomly drawn. In geographic areas 
where the proportion of age, ethnic, or income groups selected for oversampling is 
high, the probability of selection for those groups is greater than in other areas. In 
stage four, individuals are chosen to participate in NHANES from a list of all persons 
residing in selected households. Individuals are drawn at random within designated 




NHANES samples larger numbers of certain subgroups of particular public 
health interest. Oversampling is done to increase the reliability and precision of 
estimates of health status indicators for these population subgroups. Examples of 
oversampled subgroups include: African Americans, MA‟s, low income white 




Human subject approval was granted for this study by the University of 





Subjects: Inclusion and Exclusion Criteria 
The study population selected for this study consisted of NHW, NHB, and 
MA male and female adults 20 years old and older, who fasted at least eight but no 
more than 24 hours, and who attended the morning in-person medical examination at 
the NHANES mobile examination centers. Pregnant and breastfeeding women, 
people with nephrotic syndrome (urinary albumin to creatinine ratio ≥ 3000) or those 
using insulin to treat their diabetes (a likely indication of type I diabetes) since all 
these are factors that are known to have an effect on blood TG and HDL levels. 
Lastly, participants of other races and ethnicities were also excluded from the 
analyses. Individuals with diabetes and women taking exogenous hormones were 
counted in for descriptive purposes, but were excluded from the analyses.  
 
Variable Selection and Definition 
 Race/ethnicity was classified according to self-report of race and/or ethnicity.  
Age group was classified into subgroups as 20 to 39, 40 to 59, and 60 years old or 
older for descriptive purposes. It was also used as a continuous variable for mean 
determination as well as for inclusion in the statistical analyses. 
Economic status was classified according to the poverty income ratio (PIR), 
for which the corresponding categories thresholds are 1, 2, 3, 4 and 5. According to 
the U.S. Census Bureau, “the income-to-poverty ratios represent the ratio of family or 
unrelated individual income to their appropriate poverty threshold. Ratios below 1.00 
indicate that the income for the respective family or unrelated individual is below the 




the poverty level. A ratio of 1.25, for example, indicates that income was 125 percent 
above the appropriate poverty threshold”
47
. Education level was divided to three 
categories: less than eight years, eight to 12 years, and more than 12 years. Health 
insurance coverage was classified as covered or not covered, according to self-
report. 
 Smoking status was defined as a categorical variable indicating past smokers, 
present smokers, and individuals who never smoked, as well as a continuous variable 
listing the amount of cigarettes smoked in the past 30 days. Past smokers were those 
who reported that they had smoked at least 100 cigarettes in their lifetime but who did 
not currently smoke cigarettes.  
Alcohol intake was defined as a continuous variable listing the amount of 
alcoholic beverages consumed in the past 30 days, as well as a categorical variable 
indicating 0 to 30 drinks, 31 to 60, 61 to 100, and over 100 drinks per month. One 
drink was considered a 12 ounce beer, five ounces of wine, and one and a half ounces 
of liquor.  
Daily physical activity level was defined as a four level categorical variable: 
1. sitting during the day and not walking about very much; 2. standing or walking 
about a lot during the day, but not carrying or lifting things very often; 3. lifting loads 
or having to climb stairs or hills often; and 4. doing heavy work or lifting heavy 
loads. Household physical activity was defined as a continuous variable measuring 
how many minutes in the last 30 days were spent doing housework chores and 
activities such as raking leaves, mowing the lawn or heavy cleaning that caused light 




effort) for at least 10 minutes. For the purpose of description, the average household 
physical activity was also categorized as 0 minutes, 1 to 450 minutes, 450 to 900 
minutes, 900 to 1,800 minutes, and more than 1,800 minutes, based on the 
distribution.  
Weight, height, and WC were measured while in the in-person 
examination using standardized techniques and equipment. WC was measured at the 
uppermost lateral border of the right ilium. Blood samples were taken to measure 
blood lipid, lipoprotein, fasting blood glucose, and CRP concentrations. Urine 
samples were taken to detect pregnancy and to detect and measure urinary albumin 
and creatinine levels.   
BMI was calculated from weight and height measurements obtained in-person 
at the mobile examination center and by dividing weight in kilograms by the square 
of height in meters. Overweight and obesity were defined as a BMI 25 to 29.9 and 30 
kg/m
2
 or higher, respectively, according to WHO criteria
48
.  
 Presence of the MS and presence of MS risk factors were defined using the 
ATP III criteria, where having of three out of five of the following abnormalities 
indicates the presence of the MS: elevated WC (≥ 102 cm in men, ≥ 88 cm in 
women), elevated TG (≥ 150 mg/dL, or drug treatment for elevated TG), reduced 
HDL (< 40 mg/dL in men, < 50 mg/dL in women, or drug treatment for reduced 
HDL), elevated BP (≥ 130 mm Hg systolic BP or ≥ 85 mm Hg diastolic BP, or drug 
treatment for elevated BP), and/or elevated fasting glucose (≥ 100 mg/dL, or 
treatment for elevated glucose). In order to make more fair comparisons with 




threshold in 2004, we also calculated MS prevalences using the FPG cutoff of 110 
mg/dL. 
In order to calculate average BP up to four BP readings were measured in the 
mobile examination center. For people with three to four readings, three BP readings 
were used and averaged according to the following rules: if only one BP reading was 
obtained, that reading was considered as the average. If there was more than one BP 
reading obtained, the first reading was always excluded from the average. If only two 
BP readings were obtained, the second BP reading was considered as the average. 
Systolic blood pressure could not be greater than 300 or smaller than diastolic blood 
pressure. If there was no systolic blood pressure, then the diastolic blood pressure was 
not considered. Diastolic blood pressure could be zero but if all diastolic readings 
were zero, the average would be zero, except if there was one diastolic reading of 
zero and one (or more) with a number above zero. In this case the diastolic reading 
with zero was not used to calculate the diastolic average. If two out of three readings 
were zero, the one diastolic reading that was not zero was used to calculate the 
diastolic average. All BP measurements were obtained after a five minute seated rest 
and on the right arm. If measurement was not able to be done on the right arm, then 
the left arm was used for BP measurements. 
 Presence of CVD was determined by self-report of a physician‟s diagnosis for 
the following: heart failure, coronary heart disease, angina pectoris, heart attack, 
stroke, and HT. The latter was also considered if the measured BP measurements at 




diastolic BP or if the individual reported taking antihypertensive medication, 
according to ATP III classification. 
Presence of diabetes was determined by self-reported physician‟s diagnosis of 
diabetes and/or as undiagnosed diabetes in individuals with blood glucose levels ≥ 
126 mg/dL as measured in the mobile examination center.  
Menopausal status was defined in women by self-report of cessation of 
periods and/or of removal of both ovaries.  
Use of lipid and lipoprotein medication was assessed by reported intake of 
HMG-CoA reductase inhibitors (statins), fabric acid derivates, and antihyperlipidemic 
combinations (statins and fibric acid derivates, and/or niacin or Ezentibe). These drug 
types were selected for their ability to alter TG and HDL levels in the blood. 
 
Basic Statistical Concerns 
Sample Design: Because the sampling design of NHANES is a complex, 
multistage, probability sampling design rather than a random sampling design, 
appropriate sampling design parameters were taken into account. In our analysis, with 
replacement (WR) design was specified through all the analysis below to account for 
the complex survey design.  
Weighting: In the NHANES datasets, a sample weight was assigned to each 
sample person. This weight is a measure of the number of people in the population 
represented by that sample person in NHANES and reflects the unequal probability of 
selection, non-response adjustments, and adjustments to independent population 




to produce an unbiased national estimate
46
. For our analysis, eight-year weights from 
1999-2006 were constructed by using the four-year weights from 1999-2002, the two 
year weights from 2003-2004, and the two year weights from 2005-2006 to provide 
estimates that were representative of the U.S. population.  
Variance Estimation: In order to ensure statistical reliability for all survey 
estimates, variance of estimates (sampling errors) were calculated. For complex 
sample surveys, general mathematical formulas for variance estimates are usually not 
available, so variance approximation procedures are required to provide reasonable 
estimates of the sampling errors. In this study, the common method Taylor Series 
Linearization procedure was executed for this purpose, which accounts for the 
complex sample design and the computed design effects. 
The detailed descriptive analyses for the variables of interest mentioned above 
were carried out as follows: 
Normality testing (for continuous variables): In order to detect outliers and 
whether or not log transformations were needed, normality tests were carried out to 
test for normality of continuous variables using the procedure UNIVARIATE in SAS.  
  Outlier determination (for continuous variables): Based on the distribution 
of the continuous variables, the outliers of each variable in each category of gender 
and race were determined and subsequently removed before performing the analyses. 
 Descriptive Statistics: For the discrete variables, population characteristics 
such as counts, prevalences, and the standard errors of prevalences were calculated. 




 For continuous variables, descriptive statistics such as means (of the non-log 
transformed variables), standard errors were obtained. For this the DESCRIPT 
procedure in SUDAAN was executed.  
Age-adjusting: As we know, age can confound comparisons when the groups 
being compared have different age distributions and when age is related to the 
outcome of interest (e.g. death or the prevalence of disease). Age-adjusting, which 
uses age standard proportions, is done to roughly remove the confounding effect of 
age in order to make more relatively fair comparisons. Age-adjusting was used in this 
analysis for the determination of prevalence of MS and CVD. The DESCRIPT 
procedure in SUDAAN was used to generate age-adjusted percentages (prevalence 
rates) and standard errors.  
 
Hypothesis Testing 
For the specific events, such as presence of MS and CVD, Chi square statistics 
were first used to detect whether or not there were significant differences between 
unadjusted prevalences of the MS and of CVD across racial/ethnic and gender groups 
using the CROSSTAB procedure in SUDAAN was executed. The specific contrasts 
between different levels of racial/ethnic and gender groups were detected by using 
logistic regression with Bonferroni adjustments for multiple comparisons. For this the 
RLOGIST procedure in SUDAAN was executed. To compare the age-adjusted 
prevalences of the MS and CVD, t-tests with and without Bonferroni adjustments 




Similarly, the significant differences across racial/ethnic groups in terms of 
prevalences of MS risk factors were determined using Chi square tests, also with 
Bonferroni adjustments for multiple comparisons. For this the CROSSTAB procedure 
in SUDAAN was executed. 
For the continuous variables, the differences between means across 
racial/ethnic groups were detected by using multiple regression analyses with 
Bonferroni adjustments for multiple comparisons. The REGRESS procedure in 
SUDAAN was executed for this purpose.  
In addition, the differences between the current prevalences of MS and the 
updated prevalence of MS using the newly calculated lipid cutoffs were detected by 
using t-tests. 
Differences in hypothesis testing were considered significant at the p ≤ 0.05 
level and extremely significant at the p ≤ 0.01 level for two-sided tests. 
 
Logistic Regression Analysis and Model Selection 
 Power analysis was performed to determine the adequate sample size needed 
to detect significant differences across racial/ethnic groups. As mentioned before, 
variables used in the regression analysis were examined for outliers, which were 
subsequently removed. The explanatory variables were tested for normality and 
linearity with the response variable, as well as for homogeneity of residual variances. 
Additionally, the explanatory variables were tested for interactions and no significant 




performed logarithmic transformations for TG, HDL, LDL, and CRP due to their 
non-normal distributions.  
Logistic regression analyses were performed to assess the association of 
logTG and logHDL with presence of the MS, while adjusting for potential 
confounders. The logistic regression model was formulated as follows: The vector of 
observations y, i.e. presence of the MS was distributed as a binary distribution, i.e. 
y~Bi(1, π); the linear predictor was expressed as: (logit (π) = βx, where π was the 
vector of probabilities for presence of the MS when all the other parameters β were 
applied. β was the vector of all effects that might influence the presence of the MS, 
and includes the variables age, gender, race/ethnicity, education , income (PIR), 
health insurance coverage (yes/no), smoking status (past, present, never), number of 
drinks in the past 30 days, daily average physical activity (categorical variable levels 
1-4), minutes of household chores activity in the past 30 days,  BMI (overweight and 
obese), WC, average systolic BP, average diastolic BP, logTG, logHDL, log LDL, 
blood glucose, and log CRP.  Logit (π) = ln (π /1- π) was the link function for the 
analysis. Standardized regression coefficients were estimated to enable comparisons 
across variables with different metric scales. Odds ratios and their upper and lower 
limits were estimated from the logistic regression analysis and based on the 
standardized regression coefficients. The RLOGIST procedure in SUDAAN was 







Determination of the New Lipid and Lipoprotein Cutoffs 
The Receiver Operating Characteristic (ROC) curve is a useful method to 
determine precise and accurate cutoffs of the predictor variables of interest. The basic 
theory for ROC curve analysis is as follows: 
For each predictor variable of interest (in our case TG and HDL), a series of 
cutoffs Xi (i=1, 2,…c) are proposed. For each Xi, frequencies of true positives (TP), 
false positives (FP), false negatives (FN), and true negatives (TN) are estimated 
according to the classifications on table 8. In the table, the columns represent the true 
or actual condition and the rows represent the predicted test results.   
 



















(TP + FP) = 
all positive 
tests 




(FN + TN) = 
all negative 
tests 
Total (TP + FN) = 
all true 
positives 
(FP + TN) = 
all true 
negatives 
N (total sample 
size) 
 
Using the information on this table, estimates of sensitivity and specificity and 
related statistics were calculated using the corresponding formulas: 
Sensitivity (SN) = TP / [TP + FN]  
Ability of the test to correctly identify those cases with the condition. 
 




Ability of the test to correctly identify those cases that do not have the condition. 
 
Positive Predictive Value (PPV) = TP/ TP + FP 
The proportion of cases that have the condition among those classified without the 
condition. 
 
Negative Predictive Value (NVP) = TN/ FN + TN 
The proportion of cases that do not have the condition among those classified without 
the condition. 
 
Youden Index = SN + SP – 1 
Overall measure of test accuracy (+1 is perfect prediction). 
 
Total Accuracy (TA) = TP + TN/ N 
The proportion of cases whose tests accurately predict the true outcome. 
 
Matthews Correlation Coefficient (MCC) =  TPTN – FPFN/ √(TP + FN)(TP + 
FP)(TN + FP)(TN + FN) 
Another overall measure of test accuracy (+1 is perfect prediction). 
 
 
A ROC curve is drawn by plotting sensitivity versus specificity for each cutoff 
(see Appendix B: Figures 4, 8 & 12). Usually, the ultimate optimal cutoff is 
determined by maximizing both sensitivity and specificity, which is equivalent to 
maximizing the Youden Index. The better the classification, the closer the curve will 
be to the upper left corner of the plot. A Youden Index value of +1 indicates perfect 
prediction as it achieves both 100 percent sensitivity and 100 percent specificity. A 
Youden Index value of 0.5 indicates that the test is not better than random 
classification. Calculations of the Total Accuracy (TA) and Matthew Correlation 
Coefficient (MCC) can also be used to determine the optimal cutoff points. 
For our analysis, the ROC curve method was used to determine the most 
sensitive and specific cutoff values of TG and HDL to detect the presence of the MS 




separately for males and females due to the fact that the current recommendations 
include distinct values for both genders.  
The cutoffs (Xi) for TG and HDL were calculated according to the following 
formula: cutoff = minimum value of TG or HDL + (I – 1) (maximum value of TG or 
HDL – minimum value of TG or HDL)/x, where x equaled 300 or 50, and I was an 
integer from one to x + 1. The maximum values used were the relative values based 
on distribution rather than the exact maximums. For TG this maximum value was 300 
mg/dL and for HDL, 110 and 120 mg/dL were considered the maximum values for 
males and females, respectively. The minimum values used were the exact minimum 
values. To determine the optimum cutoff value, 300 was used as the denominator (x), 
while 50 was used as the denominator (x) when drawing the ROC curve. For each 
cutoff, sensitivity and specificity were calculated as well as the Youden Index, which 
was used to determine the optimum cutoffs for TG and HDL. The ROC curves of 
calculated sensitivity versus specificity were drawn under R environment. 
For purposes of cross-examination, the cutoffs were calculated using the exact 
values of TG and HDL. For this, logistic regression analyses were performed. Also 
for cross examination, sensitivity, specificity, Youden Index, TA and MCC were 
calculated and plotted and used to confirm the cutoffs previously determined. Here 
the maximum value of the Youden Index was utilized to determine the optimal cutoff 
points for TG and HDL in each group. The plots of sensitivity and specificity, the 
Youden Index, TA, and MCC were plotted using SAS.  
All statistical analyses and plots were calculated and conducted using SAS 




Chapter 5:  Results 
 
The study population consisted of 6,306 male (51.41%) and female (48.59%) 
adults ages 20 and over. Of these 23.50 percent were MA (52.63% male, 47.37% 
female), 55.96 percent were NHW (51.83% male, 48.17% female), and 20.54 were 
NHB (48.88% male, 51.12% female) (Table 9). 
 
Population Characteristics: Means of Socioeconomic and Lifestyle Factors 
The mean age of the population was 46.41 ± 0.41 years. On average, NHW‟s 
(47.89 ± 0.46) were significantly older than MA‟s (38.81 ± 0.55) and NHB‟s (42.98 ± 
0.48). The average population PIR was 3.12 ± 0.05 meaning that the average PIR was 
312 percent over the national poverty line. MA‟s had the lowest average PIR (2.05 ± 
0.07), followed by NHB‟s (2.46 ± 0.07), and lastly by NHW‟s (3.31 ± 0.06), who had 
the highest average PIR scores. All groups were significantly different from each 
other in terms of PIR. The average number of cigarettes smoked in the past 30 days 
for smokers was 2.65 ± 0.55. There were no significant differences in the average 
number of cigarettes smoked across groups. The average number of alcoholic 
beverages drunk in the past 30 days was 19.75 ± 0.67. NHW‟s drank significantly 
more alcoholic beverages on average per month (20.02 ± 0.83) as compared to MA‟s 
(17.96 ± 1.26) and NHB‟s (18.74 ± 1.99) (Table 10). 
In terms of minutes of household physical activities performed in the past 30 




significantly more active in housekeeping activities than MA‟s (316.69 ± 28.52) and 
NHB‟s (290.71 ± 24.81), who were the least active in this category (Table 10).  
 
Population Characteristics: Prevalences of Socioeconomic and Lifestyle Factors 
In terms of education, the highest prevalence fell upon the more than 12 years 
education group (54.87% ± 1.26), with NHW‟s having the highest prevalence in this 
education subgroup (58.82% ± 1.53) versus MA‟s (25.68% ± 1.61) and NHB‟s 
(48.01% ± 1.73). MA‟s had the highest prevalence of individuals with less than 12 
years education (53.14 ± 1.73) compared to NHW‟s (12.76% ± 0.93) and NHB‟s 
(28.14% ± 1.80). NHW‟s also had a higher prevalence (86.67% ± 0.99) of health 
insurance coverage as compared to MA‟s (50.89% ± 2.47) and NHB‟s (75.86% ± 
1.87) (Table 13). 
  NHW‟s had the highest prevalence of past smokers (48.07 ± 1.43), NHB‟s 
had the highest prevalence of present smokers (62.99 ± 2.32), and MA‟s had the 
highest prevalence of people who had never smoked (10.61 ± 2.13). When it came to 
drinking status all groups had a prevalence of roughly 80 percent of individuals who 
drank from 0 to 30 alcoholic beverages in the past 30 days (Table 13). 
On average, all groups had the highest number of individuals whose daily 
physical activity level was (2) standing or walking about a lot during the day, but not 
carrying or lifting things very often (all groups prevalence 49.89% ± 0.92). NHB‟s in 
particular had 54.15% ± 1.58 of its population in this group compared to MA‟s 




The prevalence of all menopausal women in the sample was 27.95 percent ± 
1.30. NHW women had the highest prevalence of menopausal women (30.00% ± 
1.63), followed by NHB women (21.75% ± 2.36), and lastly by MA women (15.95% 
± 2.30) (Table 15). 
 
Means of Metabolic Syndrome Risk Factors     
 The total population‟s mean BMI was 28.35 ± 0.11 with NHB‟s being 
significantly more overweight than MA‟s and NHW‟s (29.86 ± 0.22 vs. 28.48 ± 0.16 
MA and 28.12 ± 0.14 NHW) (Table 9).  In terms of WC, NHW men had the highest 
mean WC (101.73 ± 0.45) compared to MA men (96.88 ± 0.76) and NHB men (95.57 
± 0.77) (Table 11). On the other hand, NHW women had significantly lower mean 
WC (92.95 ± 0.50) compared to MA women (94.94 ± 0.69) and NHB women (99.04 
± 0.64), who had the highest mean WC among women (Table 12). 
 As was expected, NHB‟s had significantly higher mean HDL levels (55.04 ± 
0.47) compared to MA‟s (49.39 ± 0.43) and NHW‟s (52.94 ± 0.37). Also as expected, 
NHB‟s had significantly lower mean TG levels (105.91 ± 2.22) compared to MA‟s 
(149.65 ± 4.62) and NHW‟s (144.09 ± 2.01). NHB‟s had significantly higher mean 
systolic BP (126.04 ± 0.61) and mean diastolic BP (73.45 ± 0.36) than MA‟s (119.02 
± 0.68 systolic, 70.52 ± 0.40 diastolic) and NHW‟s (122.15 ± 0.39 systolic, 71.60 ± 
0.32 diastolic). NHB‟s had similar mean FPG levels (100.15 ± 0.75) than NHW‟s 
(100.29 ± 0.51) but MA had significantly higher mean FPG levels (102.13 ± 0.98) 
compared to NHW‟s and NHB‟s. NHB‟s also had a significantly lower mean TG to 




Lastly, NHB‟s had significantly higher mean CRP (0.51 ± 0.03) as compared to MA‟s 
(0.42 ± 0.02) and NHW‟s (0.38 ± 0.01) (Table 10). 
 
Prevalences of Metabolic Syndrome Risk Factors 
NHB‟s had the lowest percent of overweight individuals compared to MA‟s 
and NHW‟s (28.40% ± 1.34 vs. 40.59% ± 1.70 MA and 34.11% ± 1.00 NHW), but 
had the highest percent of obese individuals (44.28% ± 1.53 vs. 32.37% ± 1.37 MA 
and 31.26% ± 0.96 NHW). In terms of elevated WC, NHB‟s had the highest 
prevalence (54.62% ± 1.61) although compared to NHW‟s (52.50% ± 1.17) these 
prevalences were not significantly different. MA‟s had a significantly lower elevated 
WC prevalence (48.22% ± 2.05) compared to NHB‟s but not to NHW‟s (Table 17). 
As it is expected and as the group means have already indicated, NHB‟s had a 
significant lower prevalence of low HDL levels (30.54% ± 1.46) compared to MA‟s 
(39.68% ± 1.78) and NHW‟s (39.43% ± 1.09). NHB‟s also had a significantly lower 
prevalence of elevated TG levels (22.30% ± 1.24) compared to MA‟s (38.36% ± 
1.95) and NHW‟s (40.64 ± 1.09) (Table 17). 
NHB‟s had a significantly higher prevalence of HT (49.38% ± 1.59) 
compared to MA‟s (26.94% ± 1.70) and NHW‟s (42.65% ± 1.03), as well as a 
significant higher prevalence of diabetes (12.09% ± 0.90) compared to NHW‟s 
(8.99% ± 0.56), but not compared to MA‟s (10.39% ± 1.21). In terms of elevated 
FPG, MA‟s had a significantly higher prevalence as compared to NHW‟s (40.73 ± 
1.99), but not as compared to NHW‟s (37.59 ± 1.40). When the threshold for FPG of 




were observed between all racial/ethnic groups (17.11% ± 1.44 MA, 15.72% ± 0.76 
NHW and 15.31% ± 1.07 NHB). It is important to note that all elevated FPG 
prevalences were more than doubled when using the current FPG cutoff of 100 
mg/dL versus the previously established FPG cutoff of 110 mg/dL (Table 17). 
 
Prevalence of the Metabolic Syndrome 
The age-adjusted prevalence of the MS for the total population was 38.14 
percent (± 0.87), with the age-adjusted prevalence being significantly higher in males 
(40.51% ± 1.06) than in females (35.73% ± 1.15). The age-adjusted prevalence of the 
MS was higher among MA‟s (41.03% ± 1.48), followed by NHW‟s (38.51% ± 1.09) 
and lastly by NHB‟s (34.49% ± 1.11), who had the lowest prevalence of the MS in 
agreement with the reported lower MS prevalence rates among NHB‟s. Among men, 
NHW men had the highest age-adjusted MS prevalence (42.35% ± 1.21), followed by 
MA men (37.96% ± 2.00), and lastly by NHB men (29.08% ± 1.95). All the MS 
prevalence estimates among men were significantly different. The pattern of MS 
prevalence was different for women with MA women (43.98% ± 1.74) having the 
greatest prevalence, followed by NHB women (38.85% ± 1.50), and last by NHW 
women (34.64% ± 1.45). All the MS prevalence estimates among women were 
significantly different as well (Table 19). 
Using the previous FPG cutoff of 110 mg/dL the prevalences of the MS were 
markedly lower across all groups. Using this cutoff the age-adjusted prevalence of the 
MS for the total population was 32.29 percent (± 0.73), with the age-adjusted 




(30.99% ± 1.09). The age-adjusted prevalence of the MS was higher among MA‟s 
(34.38% ± 1.58), followed by NHW‟s (32.75% ± 0.89) and lastly by NHB‟s (28.38% 
± 1.17), who had the lowest prevalence of the MS in agreement with the reported 
lower MS prevalence rates among NHB‟s. Among men, NHW men had the highest 
age-adjusted MS prevalence (35.07% ± 1.22), followed my MA men (31.41% ± 
1.99), and lastly by NHB men (24.24% ± 1.76). All the MS prevalence estimates 
among men were significantly different. The pattern of MS prevalence was different 
for women with MA women (37.22% ± 1.80) having the greatest prevalence, 
followed by NHB women (31.77% ± 1.50), and last by NHW women (30.43% ± 
1.38). Like for males, all the MS prevalence estimates among women were 
significantly different. All in all the total group MS prevalence increased by an 
average of five percentage points when utilizing the current FPG cutoff of 100 mg/dL 
(38.14% ± 0.87) as compared to using the previous cutoff point of 110 mg/dL 
(32.29% ± 0.73) (Table 20). 
 
Prevalence of Cardiovascular Disease  
The age-adjusted CVD prevalence for the entire study population was 38.82 
percent (± 0.78), with males having a significantly higher CVD age-adjusted 
prevalence (39.84% ± 1.05) than women (37.66% ± 1.08). In accordance to 
previously reported CVD age-adjusted prevalence rates, NHB‟s had a significantly 
higher prevalence of CVD (46.71% ± 1.14) compared to MA‟s (33.37% ± 1.38) and 
NHW‟s (38.45% ± 0.89). NHB men had significantly higher age-adjusted CVD 




(40.29% ± 1.20) counterparts. The same was true for NHB women (48.08% ± 1.91 
vs. 34.65% ± 2.05 MA and 36.48% ± 1.29 NHW). NHB (44.78% ± 2.13) and MA 
(31.90% ± 1.68) men had significantly lower age-adjusted CVD prevalences than 
NHB (48.08% ± 1.91) and MA women (34.65% ± 2.05), respectively, but NHW men 
had significantly a higher age-adjusted CVD prevalence (40.29% ± 1.20) compared to 
NHW women (36.48% ± 1.29) (Table 21). 
 
Logistic Regression Analysis 
 When the logistic regression model was fit we observed that the variables age 
(p= 0.0110), gender (p=0), smoking status (p=0.0429), BMI (p=0.0726), WC 
(p=0.0002), systolic BP (p=0.0001), FPG (p=0), logTG (p=0), logHDL (p=0), and 
logLDL (p=0) were significant predictors of MS. On the other hand, race/ethnicity, 
economic status (PIR), education, health insurance coverage, smoking status, daily 
activity level, household physical activity, diastolic BP, and log CRP were not 
significant predictors of the MS. The R
2
 value that resulted from the model equaled 
0.472761, hence approximately 47 percent of the variability in MS was accounted for 
by the joint predictive ability of the significant model variables (Table 22). 
 The parameter estimators (β coefficients) for the significant variables that 
resulted from the logistic regression analysis were as follows: -1.43 ± 0.31 for male 
(gender),0.02 ± 0.01 for age, 0.09 ± 0.02 for WC, 0.04 ± 0.01 for systolic BP, 0.11 ± 
0.01 for FPG, 2.07 ± 0.22 for logTG, -2.64 ± 0.47 for logHDL, and -1.62 ± 0.28 for 
logLDL. The estimators for race/ethnicity, education, smoking status, health 




alcohol intake, BMI, diastolic blood pressure, and logCRP were not significant (Table 
23). 
  When examining the odds ratio that resulted from the logistic regression 
analysis we can appreciate that being male significantly decreased the odds of having 
the MS by 76 percent as compared to being female. In terms of race/ethnicity, MA‟s 
had 54 percent higher odds of having the MS as compared to NHB‟s and NHW‟s had 
22 percent increased odds of having the MS as compared to NHB‟s, although these 
trends were not significant. On the other hand, the odds ratios for race/ethnicity, 
education, smoking status, health insurance coverage, and daily activity level were 
not significant among the categorical variables included in the model (Table 24).  
 When examining the odds ratios for the continuous variables we can observe 
that for a one unit increase in age, the odds of having the MS increased two percent. 
For a one unit increase in WC, there was and nine percent increase in the odds of 
having the MS. For every one unit increase in systolic blood pressure the odds of 
having the MS increased four percent. For every one unit increase in FPG, the odds of 
having the MS increased ten percent. In terms of TG, for every one unit increase in 
logTG, the odds of having the MS increased 7.89 times. Conversely, for every one 
unit increase in logHDL, the odds of having the MS decreased 93 percent. 
Interestingly, for every one unit increase in logLDL, the odds of having the MS 
decreased by 80 percent. Meanwhile, the odds ratios for economic status (PIR), 
household activity, alcohol intake, BMI, diastolic BP, and logCRP were not 





New TG and HDL Cutoff Determination 
 After drawing ROC curves and calculating the Youden Index for TG by 
racial/ethnic group we obtained the following optimal TG cutoffs: 137 mg/dL for 
MA‟s, 140 mg/dL for NHW‟s, and 110 mg/dL for NHB‟s (Figures 4-7). 
When conducting the TG cutoff calculations using the FPG cutoff of 110 
mg/dL we obtained the following optimal TG cutoffs: 140 mg/dL for MA‟s, 149 
mg/dL for NHW‟s, and 121 mg/dL for NHB‟s. 
 ROC curves were drawn and the Youden Index calculated for HDL by 
race/ethnicity and by gender. The calculated optimal HDL cutoff values for males 
were as follows: 40 mg/dL for MA‟s, 40 mg/dL for NHW‟s, and 42 mg/dL for 
NHB‟s (Figures 8-11). The same was done for HDL cutoffs in females and the 
following resulted: 50 mg/dL for MA‟s, 50 mg/dL for NHW‟s, and 50 mg/dL for 
NHB‟s (Figures 12-15). 
When conducting the HDL cutoff calculations for males using the FPG cutoff 
of 110 mg/dL we obtained the following: 40 mg/dL for MA‟s, 39 mg/dL for NHW‟s, 
and 40 mg/dL for NHB‟s. The same was done for HDL cutoffs in females and the 
following resulted: 50.5 mg/dL for MA‟s, 49.5 mg/dL for NHW‟s, and 49.5 mg/dL 
for NHB‟s. 
 As we can observe new TG values were suggested for all racial/ethnic groups. 
In particular, looking at the suggested values of 137mg/dL for MA‟s and 110mg/dL 
for NHB‟s, we can see that they stand in stark contrast to the current universal cutoff 




groups were close enough to the currently established cutoff values of 40mg/dL for 
males and 50mg/dL for females. 
 
Prevalence of the Metabolic Syndrome Based on the Newly Determined TG Cutoffs 
 Using the proposed new cutoffs of 137 mg/dL for MA‟s, 140 mg/dL for 
NHW‟s, and 110 mg/dL for NHB‟s we arrived at the following MS prevalence 
estimates. The new age-adjusted prevalence would be 39.83% ± 0.86 versus the 
current age-adjusted prevalence of 38.14% ± 0.87 (p < 0.01). For MA‟s the new age-
adjusted prevalence would be 42.19% ± 1.49 versus the current age-adjusted 
prevalence of 41.03% ± 1.48. The new age-adjusted prevalence for NHW‟s would be 
39.86% ± 1.06 versus the current age-adjusted prevalence of 38.51% ± 1.09. For 
NHB‟s the new age-adjusted MS prevalence would be 38.23% ± 1.08 in contrast to 
the current age-adjusted prevalence of 34.49% ± 1.11 (p < 0.01). The age-adjusted 
MS prevalences calculated for the new cutoffs remained significantly different across 
all racial/ethnic groups (Table 25). 
 For males the new age-adjusted prevalence would be 41.86% ± 1.05 in 
contrast to the current age-adjusted prevalence of 40.51% ± 1.06 (p < 0.01). For MA 
males the new age-adjusted MS prevalence would be 38.63% ± 1.97 versus the 
current age-adjusted prevalence of 37.96% ± 2.00. For NHW males the new age-
adjusted MS prevalence would be 43.55% ± 1.20 versus the current age-adjusted 
prevalence of 42.35% ± 1.21 (p < 0.01). For NHB males the new age-adjusted MS 




of 29.08% ± 1.95 (p < 0.01). The age-adjusted prevalences remained significantly 
different across all racial/ethnic groups (Table 25). 
For females the new age-adjusted prevalence would be 37.80% ± 1.18 versus 
the current age-adjusted prevalence of 35.73% ± 1.15 (p < 0.01).  For MA females the 
new age-adjusted prevalence would be 45.69% ± 1.86 versus the current age-adjusted 
prevalence of 43.98% ± 1.74. For NHW females the new age-adjusted prevalence 
would be 36.35% ± 1.45 versus the current age-adjusted prevalence of 34.64% ± 
1.45. For NHB females the new age-adjusted MS prevalence would be 43.38% ± 1.57 
in contrast to the current age-adjusted prevalence of 38.85% ± 1.50 (p < 0.01). Here 
also the age-adjusted prevalences remain significantly different across all 
racial/ethnic groups (Table 25). 
For descriptive purposes the same statistics were calculated utilizing the FPG 
cutoff of 110 mg/dL for the determination of MS prevalence. These results are 




Chapter 6:  Discussion and Conclusions 
 
It has been observed over the years that blacks in the country have higher rates 
of CVD, diabetes, insulin resistance, HT, and obesity as compared to whites
30, 49-51
. 
Paradoxically, in spite of this they have lower prevalence rates of the MS, which 
purpose essentially is to help detect and prevent these same conditions. It is argued 
that this is due to the fact that blacks have lower TG levels and higher HDL levels 
compared to other racial/ethnic groups, which means that they do not as easily meet 
the lipid and lipoprotein criteria proposed to detect the MS. The goal of this study was 
to find new TG and HDL cutoffs that would accommodate these lipid and lipoprotein 
variations in NHB‟s and to further support that definitions for the MS should reflect 
these kinds of variations across racial/ethnic groups.  
 In our study we were able to see the same expected patterns of risk factors that 
have been identified in the black populations in the country through various surveys, 
among these, earlier versions of NHANES. As this analysis of NHANES data shows, 
NHB‟s smoke more and perform less household physical activity as compared to 
NHW‟s and MA‟s. Furthermore, they have lower average incomes, education, and 
health insurance coverage when compared to NHW‟s. NHB‟s are less overweight but 
more obese than NHW‟s and MA‟s. NHW men have lower WC as compared NHW‟s, 
but NHB women have the highest WC among the three racial/ethnic groups. As 
expected, NHB‟s have the lowest average serum TG levels as well as highest average 
serum HDL levels. They also have the lowest prevalences of elevated TG and of low 




and a higher HT prevalence when compared to MA‟s and to NHW‟s. In terms of 
diabetes they also have a higher prevalence when compared NHW‟s. All in all, 
NHB‟s have the highest prevalence of CVD and CVD risk factors but the lowest 
prevalence of MS of all the racial and ethnic groups. It is exactly this scenario that 
calls into question the validity of the current criteria for the detection of the MS 
syndrome in blacks.  
Unadjusted and age-adjusted prevalences of the MS based on NHANES III 
(1988-1994) were 21.8 percent and 23.7 percent, respectively. MA‟s had the highest 
age-adjusted prevalence of the MS (31.9%), followed by NHW‟s (23.8%) and NHB‟s 
(21.6%)
30
. Our results based on NHANES 1999-2006 and using the previous FPG 
cutoff of 110 mg/dL (in order to make fair comparisons), indicate that the most 
current unadjusted and age-adjusted MS prevalence have since then increased to 
32.86 percent and 32.29 percent, respectively. Using this FPG cutoff, among MA‟s 
the age-adjusted prevalence has increased to 34.38 percent, among NHW‟s to 32.75 
percent, and among NHB‟s to 28.38 percent. The greater prevalences likely reflect 
the ever-increasing overweight and obesity rates in the country as well as the 
population growth that has taken place in the time period from the late 1980‟s to the 
late 2000‟s
30
. Utilizing the newly proposed FPG cutoff of 100 mg/dL, the unadjusted 
and age-adjusted prevalences increase an average of approximately five percentage 
points up to 38.80 percent and 38.14 percent, respectively. Using this FPG cutoff, 
among MA‟s the age-adjusted prevalence has increased to 41.03 percent, among 




increases in the prevalences, it is always clearly observed that NHB‟s have the lowest 
MS syndrome prevalence across all racial/ethnic groups. 
The relationships between serum lipids and lipoproteins and insulin resistance, 
the major underlying driving factor of the MS, have shown to be associated to 
different degrees in blacks as compared to whites and people of other races/ethnicities 
but the reasons are controversial and currently under investigation. Some researchers 
speculate that the reasons of the disconnect between lipid and lipoprotein levels and 
CVD levels in blacks is probably be due to the fact that in blacks the presence of 
HDL seem to be „dysfunctional‟. In other words, it is not unlikely that blacks are 
resistant to the cardioprotective effects of HDL and that the anti-inflammatory and 
antioxidant effects of HDL in blacks are impaired. It is also a possibility that in 
addition to having lowered TG levels, blacks have larger LDL particle sizes, which 
are more buoyant and less atherogenic when compared to whites
29
. In our study we 
observed that, in agreement with this statement, with increasing logLDL, the odds of 
having the MS in fact decreased.  
Another nonconventional cause for the disassociation between risk factors and 
CVD in blacks could be the role of proinflammatory cytokines, which are primarily 
derived from adipose tissue and adipocytes. These peptides include adiponectin, 
tumor necrosis factor-alpha, resistin, leptin, interlukin-6, and CRP
8, 39, 52, 53
. 
Circulating CRP concentrations tend to be higher in adults with the MS, and 
increased CRP is an independent risk factor for type 2 diabetes and CVD
52
. We 




compared to MA‟s and NHW‟s but in contrast with the current literature, our logistic 
regression analysis showed that CRP was not a significant predictor of the MS.  
Serum adiponectin has been found to be associated with improved insulin 
sensitivity and to be predictive the MS. Serum adiponectin levels are decreased in the 
presence of obesity and insulin resistance in blacks and in whites. On the other hand, 
tumor necrosis factor-alpha and interlukin-6 levels are increased in obese individuals. 
Both these cytokines have been associated with increased diabetes rates. What is 
more, blacks have greater oxidative stress as measured by F2 isoprostane levels when 
compared to whites. Here, either the generation of free oxygen radicals are higher or 
their clearance is impaired, or both, compared to whites. These disturbances in 
oxidative stress could play a greater role than that conferred by the protective effects 




Our study results indicated that being female as well as being MA, increases 
the odds of developing the MS. MS odds also increased with increasing age, WC, 
systolic blood pressure, logTG, and blood glucose. It is important to note that with 
every unit increase in logTG the odds of having the MS increased nearly eight-fold. 
This serves to support the fact that having TG as part of the MS criteria is of great 
value. Some research groups argue that the components of the ATP III MS criteria 
should be weighted differently to predict CVD in all racial/ethnic groups
8
. If this is 
the case, and in light of our findings, TG‟s predictive ability should not be weighed 




providing race/ethnic-specific TG and HDL cutoffs much like the IDF has provided 
specific WC cutoffs for different racial groups (Table 5).  
Other modifications to the criteria for the MS in blacks could also involve 
using BP as a base requirement for detection of the syndrome, much like central 
obesity is for the IDF definition and insulin resistance is for the WHO and EGIR 
definitions (Tables 5-7). This is due to the well established fact that blacks have 
higher prevalence of HT as well as suffer more severe consequences from it
9
.  
The main goal of our study was precisely to illustrate if different TG and HDL 
cutoffs should be instituted in the ATP III definition of the MS. We succeeded in 
finding that the TG level most indicative of the MS in NHB‟s is 40 points lower than 
that currently suggested by the ATP III criteria of 150 mg/dL. In this sense, our 
results further support to our hypothesis that lower TG lipid cutoffs would accomplish 
exactly this. We also observed that that for MA‟ a more predictive cutoff is 13 points 
lower that the currently proposed TG cutoff. Surprisingly, we also observed a new 
TG cutoff for NHW‟s that is 10 points lower than the currently proposed cutoff. An 
interesting observation is that when using the previously established FPG cutoff of 
110 mg/dL the TG cut off for all groups was about 10 points higher, in which case the 
currently established TG cutoff for NHW‟s would prove to be adequate. This points 
to the fact that when the FPG threshold levels were decreased by 10 points, perhaps 
this should have been followed by a concurrent 10 point decrease in the TG threshold. 
These differences in lipid threshold levels are enough to significantly increase 
the prevalence of the MS not only for NHB‟s, but also for the study population as a 




unadjusted and age-adjusted MS prevalences and observed that even though this 
prevalence increased only by 1.69 percentage points, this increase was enough to be 
statistically significant. Furthermore, using the new TG of 110mg/dL for NHB‟s the 
age-adjusted prevalence of the MS for NHB‟s increased by a very significant 3.74 
percentage points. The same pattern was observed for MA and for NHW men and 
women in that the MS prevalences increased modestly but nonetheless significantly 
with the newly proposed TG cutoffs. 
In addition to revealing new cutoffs for TG, we set out to find new HDL 
cutoffs for NHB‟s. Unfortunately, we were not able to identify HDL levels that were 
convincingly different than the 40 mg/dL currently recommended for detecting MS in 
men and the 50 mg/dL in women. The same was observed for MA‟s and NHW‟s. 
Nonetheless, these results support the fact that the current ATP III HDL cutoff criteria 
are set at adequate levels to detect the MS in NHB, NHW, and MA men and women. 
In relation to our research hypothesis, these results fail to support the premise that 
higher HDL cutoffs would be more adequate to detect MS in NHB‟s. 
In summary, approximately 38 percent of U.S. adults have the MS as defined 
by ATP III. NHB‟s have the lowest prevalence of the MS despite of the fact that they 
have the highest CVD prevalence in the country. This disconnect is likely due in part 
to racial and ethnic differences in lipid and lipoprotein metabolism. In light of this we 
set out to find more accurate and precise TG and HDL cutoffs for the prediction of 
CVD and diabetes risk. Our results confirm that a “one-size fits all” definition for the 
MS is not equally useful among racial and ethnic populations. With the increases in 




elderly people expected in the future, it is imperative that physicians and patients are 
provided with the appropriate and effective tools to counteract the impending 
increased risks of chronic disease.  
 
Importance and Benefits of this Study 
In light of the increasing obesity, diabetes, and CVD epidemic the country is 
facing and will increasingly continue to face, we anticipate that the results of this 
study serves to provide more adequate lipid and lipoprotein parameters for the 
detection of MS among blacks. The definition of the MS was developed as an 
instrument to detect insulin resistance and risk for diabetes and CVD with the 
expectation that physicians and patients may be warned in time to prevent these often 
deadly chronic diseases. However, as the current research literature states, the current 
definition of the MS is only an adequate tool for the identification of the MS in some 
segments of the population but not in others, and particularly among blacks. 
It was the purpose of our study to use data representative of the U.S. 
population to find lipid and lipoprotein parameters, particularly TG and HDL, that are 
indicative of the presence of the MS among U.S. blacks. Through our findings we 
aim to shed light on the fact that the current criteria used to detect metabolic 
abnormalities in this group should be revisited and revised, which may help 
physicians of African American patients to more effectively screen for risk of 
diabetes and CVD. Furthermore, we expect that researchers and epidemiologists will 




they work to make it a more effective instrument for the detection and prevention of 

























Appendix A: Tables 
 

























     
Males 51.41 (3242) 52.63 (780) 51.83 (1829) 48.88 (633) 
     


















Table 10. Population characteristics (means ± S.E) 
 
 All races/        
ethnicities 
(mean ± S.E., CI)) 
Mexican  
Americans      
(mean ± S.E., (CI)) 
Non-Hispanic  
whites              
(mean ± S.E., (CI)) 
Non-Hispanic  
blacks              




46.41 ± 0.41  
(45.79-47.43)  
 
38.81 ± 0.55†  
(37.71-39.91) 
 
47.89 ± 0.46‡  
(46.98-48.81) 
 




 (PIR)  
 
3.12 ± 0.05    
(3.03-3.21) 
 
2.05 ± 0.07†    
(1.91-2.20) 
 
3.31 ± 0.06‡    
(3.20-3.43) 
 
2.46 ± 0.07§    
(2.33-2.59)  
 
Number cigarettes  
per month 
 
2.65 ± 0.55    
(1.55-3.74) 
 
2.31 ± 0.42    
(1.46-3.16) 
 
2.72 ± 0.68   
(1.36-4.07) 
 
2.40 ± 0.59    
(1.22-3.58) 
 
Number of drinks 
per month 
 
19.75 ± 0.67  
(18.41-21.08) 
 
17.96 ± 1.26  
(15.43-20.48) 
 
20.02 ± 0.83‡  
(18.37-21.68) 
 




activity per month 
 
589.88 ± 34.17 
(521.50-658.26) 
 
316.69 ± 28.52 
(259.62-373.76) 
 
658.97 ± 39.22‡ 
(580.50-737.45) 
 






28.35 ± 0.11  
(28.12-28.58) 
 
28.48 ± 0.16†  
(28.15-28.81) 
 
28.12 ± 0.14  
(27.84-28.40) 
 






199.61 ± 0.89 
(197.84-201.39) 
 
195.95 ± 1.34† 
(193.26-198.64) 
 
201.06 ± 1.01‡ 
(199.04-203.08) 
 






119.10 ± 0.77 
(117.56-120.63) 
 
117.67 ± 1.15  
(115.37-119.97) 
 
119.72 ± 0.88  
(117.96-121.48) 
 






2.89 ± 0.30  
(52.29-53.49) 
 
49.39 ± 0.43†  
(48.53-50.25) 
 
52.94 ± 0.37‡  
(52.20-53.69) 
 






140.31 ± 1.77 
(136.77-143.85) 
 
149.65 ± 4.62† 
(140.40-158.90) 
 
144.09 ± 2.01  
(140.07-148.12) 
 
105.91 ± 2.22§ 
(101.46-110.36) 
 
Systolic blood  
pressure 
 
122.34 ± 0.36 
(121.63-123.05) 
 
119.02 ± 0.68† 
(117.66-120.38) 
 
122.15 ± 0.39‡ 
(121.37-122.94) 
 






71.72 ± 0.27  
(71.17-72.27) 
 
70.52 ± 0.40†  
(69.72-71.31) 
 
71.60 ± 0.32‡  
(70.96-72.24) 
 






100.58 ± 0.45  
(99.69-101.47) 
 
102.13 ± 0.98† 
(102.13-106.07) 
 
100.29 ± 0.51‡  
(99.27-101.31) 
 





0.40 ± 0.01    
(0.38-0.42) 
 
0.42 ± 0.02    
(0.37-0.46) 
 
0.38 ± 0.01    
(0.36-0.40) 
 





3.13 ± 0.05  
(3.02-3.23)  
 
3.52 ± 0.16† 
(3.20-3.83) 
 
3.22 ± 0.06  
(3.09-3.34) 
 
2.21 ± 0.06§  
(2.09-2.32) 
† Statistically significant difference between MA and NHB 
‡ Statistically significant difference between MA and NHW 








Table 11. Population characteristics (means ± S.E) – males 
 
 All races/        
ethnicities 
(mean ± S.E. (CI)) 
Mexican  
Americans      
(mean ± S.E., (CI)) 
Non-Hispanic  
whites              
(mean ± S.E., (CI)) 
Non-Hispanic  
blacks              
(mean ± S.E., (CI)) 
Age 45.37 ± 0.46  
(44.44-46.29) 
37.57 ± 0.56†  
(36.46-38.68) 
46.70 ± 0.53‡  
(45.65-47.75) 
42.05 ± 0.66§  
(40.76-43.37) 
 
Economic status  
(PIR) 
 
3.22 ± 0.05    
(3.12-3.32) 
 
2.07 ± 0.08†    
(1.91-2.23) 
 
3.44 ± 0.07‡    
(3.31-3.57) 
 






2.74 ± 0.64    
(1.46-4.02) 
 
3.44 ± 0.76    
(1.91-4.96) 
 
2.50 ± 0.79    
(0.92-4.07) 
 






27.90 ± 1.10  
(25.70-30.10) 
 
24.17 ± 1.66  
(20.86-27.49) 
 
29.42 ± 1.39  
(25.63-31.21) 
 




activity per month 
 
656.92 ± 41.26 
(574.36-739.48) 
 
304.75 ± 31.21 
(242.29-367.21) 
 
748.77 ± 47.93‡ 
(652.87-844.67) 
 






28.29 ± 0.13  
(28.02-28.56) 
 
27.90 ± 0.25  
(27.39-28.41) 
 
28.41 ± 0.16  
(28.08-28.73) 
 





100.64 ± 0.39  
(99.86-101.42) 
 
96.88 ± 0.76  
(95.35-98.41) 
 
101.73 ± 0.45‡ 
(100.82-102.64) 
 
95.57 ± 0.77§  
(94.04-97.11) 
 
Systolic blood  
pressure 
 
123.24 ± 0.41 
(122.42-124.05) 
 
120.11 ± 0.77† 
(118.56-121.66) 
 
123.11 ± 0.45‡ 
(122.21-124.01) 
 






72.94 ± 0.29  
(72.36-73.51) 
 
70.99 ± 0.63†  
(69.73-72.26) 
 
72.92 ± 0.32‡  
(72.28-73.56) 
 






197.67 ± 1.06 
(195.56-199.79) 
 
198.80 ± 1.64† 
(195.52-202.09) 
 
198.41 ± 1.25  
(195.91-200.91) 
 






120.36 ± 0.89 
(118.58-122.13) 
 
122.49 ± 1.34† 
(119.82-125.17) 
 
120.60 ± 1.07  
(118.46-122.74) 
 






47.53 ± 0.34  
(46.85-48.20) 
 
46.27 ± 0.45†  
(45.38-47.16) 
 
47.14 ± 0.41  
(46.32-47.97) 
 






152.69 ± 2.71 
(147.26-158.12) 
 
160.28 ± 7.49† 
(145.28-162.85) 
 
156.61 ± 3.12  
(150.36-162.85) 
 
115 ± 3.53§  
(107.93-122.07) 
 
Fasting glucose  
(mg/dL) 
 
103 ± 0.59  
(102.26-104.63) 
 
104.62 ± 1.09  
(102.44-106.79) 
 
103 ± 0.70  
(102.14-104.93) 
 





0.31 ± 0.01    
(0.29-0.34) 
 
0.31 ± 0.03    
(0.25-0.37) 
 
0.31 ± 0.01    
(0.28-0.34) 
 





3.72 ± 0.09    
(3.55-3.89) 
 
4.01 ± 0.26†    
(3.49-4.53) 
 
3.84 ± 0.10    
(3.65-4.04) 
 
2.53 ± 0.10§    
(2.34-2.73) 
† Statistically significant difference between MA and NHB 
‡ Statistically significant difference between MA and NHW 




Table 12. Population characteristics (means ± S.E) – females 
 
 All races/        
ethnicities 
(mean ± S.E. (CI)) 
Mexican  
Americans      
(mean ± S.E., (CI)) 
Non-Hispanic  
whites              
(mean ± S.E., (CI)) 
Non-Hispanic  
blacks              
(mean ± S.E., (CI)) 
Age 47.83 ± 0.46  
(46.91-48.75) 
40.46 ± 0.76†  
(38.94-41.98) 
49.06 ± 0.52‡  
(48.03-50.09) 
43.77 ± 0.72§  
(42.32-45.22) 
 
Economic status  
(PIR) 
 
3.02 ± 0.05    
(2.92-3.12) 
 
2.03 ± 0.10    
(1.84-2.23) 
 
3.19 ± 0.06‡    
(3.08-3.31) 
 
2.36 ± 0.09§    
(2.18-2.54) 
 
Number cigarettes  
per month 
 
2.56 ± 0.79    
(0.98-4.14) 
 
0.98 ± 0.25    
(0.48-1.47) 
 
2.92 ± 0.98    
(0.95-4.89) 
 






10.17 ± 0.53  
(9.11-11.23) 
 
5.25 ± 0.59†    
(4.07-6.42) 
 
10.58 ± 0.59‡  
(9.40-11.75) 
 
9.41 ± 1.36    
(6.69-12.13) 
 
Minutes household  
activity per month 
 
523.74 ± 34.84 
(454.01-593.46) 
 
332.55 ± 43.42 
(245.66-419.43) 
 
571.17 ± 40.73‡ 
(489.67-652.66) 
 






28.41 ± 0.16  
(28.08-28.73) 
 
29.25 ± 0.33†  
(28.59-29.91) 
 
27.84 ± 0.19‡  
(27.45-28.23) 
 





93.82 ± 0.40  
(93.01-94.63) 
 
94.94 ± 0.69†  
(93.57-96.32) 
 
92.95 ± 0.50  
(91.94-93.95) 
 
99.04 ± 0.64§  
(97.75-100.32) 
 
Systolic blood  
pressure 
 
121.45 ± 0.50  
(120.45-122.45) 
 
117.57 ± 1.01† 
(115.55-119.59) 
 
121.22 ± 0.58‡ 
(120.07-122.37) 
 






70.52 ± 0.34  
(69.84-71.20) 
 
69.88 ± 0.51†  
(68.87-70.89) 
 
70.31 ± 0.40  
(69.51-71.11) 
 






201.56 ± 1.06  
(199.43-203.68) 
 
192.16 ± 1.79  
(188.58-195.74) 
 
203.70 ± 1.14‡ 
(201.41-205.98) 
 






117.88 ± 1.00  
(115.88-119.88) 
 
111.48 ± 1.58  
(108.32-114.65) 
 
118.87 ± 1.08‡ 
(116.71-121.03) 
 






58.26 ± 0.48  
(57.30-59.21) 
 
53.54 ± 0.63†  
(52.27-54.81) 
 
58.71 ± 0.60‡  
(57.52-59.90) 
 






127.92 ± 1.80  
(124.31-131.54) 
 
135.58 ± 3.25† 
(129.08-142.09) 
 
131.66 ± 2.18  
(127.30-136.02) 
 
98.12 ± 2.33§  
(93.45-102.78) 
 
Fasting glucose  
(mg/dL) 
 
97.75 ± 0.49  
(96.76-98.74) 
 
103.42 ± 1.75  
(99.91-106.93) 
 
97.11 ± 0.57‡  
(95.97-98.24) 
 





0.48 ± 0.01    
(0.46-0.51) 
 
0.56 ± 0.04    
(0.48-0.63) 
 
0.45 ± 0.02‡    
(0.42-0.48) 
 





2.53 ± 0.05    
(2.43-2.63) 
 
2.86 ± 0.09†    
(2.69-3.03) 
 
2.59 ± 0.06    
(2.47-2.72) 
 
1.92 ± 0.06§    
(1.81-2.04) 
† Statistically significant difference between MA and NHB 
‡ Statistically significant difference between MA and NHW 




Table 13. Prevalence of socioeconomic and lifestyle factors 
 
 
 All races/ 
ethnicities 
(% ± S.E. (n)) 
Mexican  
Americans  
(% ± S.E. (n)) 
Non-Hispanic  
whites 
(% ± S.E. (n)) 
Non-Hispanic  
blacks 
(% ± S.E. (n)) 
Age 
  20-39 
  40-59 
  ≥ 60 
  Missing (n) 
 
36.79 ± 1.00 (1964) 
40.07 ± 0.71 (2032) 
23.14 ± 0.95 (2310) 
(0) 
 
58.79 ± 1.82 (537) 
30.41 ± 1.34 (442) 
10.79 ± 1.10 (503) 
(0) 
 
33.51 ± 1.07 (939) 
41.10 ± 0.86 (1148) 
25.39 ± 1.13 (1442) 
(0) 
 
44.08 ± 1.41 (488) 
39.68 ± 1.45 (442) 




  0 - 0.99 
  1 - 1.99 
  2 - 2.99 
  3 - 3.99 
  4 - 4.99 
  5 
  Missing (n) 
 
 
11.14 ± 0.72 (960) 
20.51 ± 0.93 (1526) 
15.60 ± 0.78 (959) 
15.21 ± 0.76 (770) 
11.01 ± 0.61 (529) 




27.73 ± 2.34 (380) 
33.39 ± 1.82(463) 
15.37 ± 1.39 (211) 
11.27 ± 1.18 (138) 
4.92 ± 0.79 (74) 




7.97 ± 0.77 (321) 
18.46 ± 1.16 (742) 
15.48 ± 0.93 (545) 
15.93 ± 0.92 (486) 
12.04 ± 0.72 (359) 




21.99 ± 1.77 (259) 
26.00 ± 1.62 (321) 
16.62 ± 1.14 (203) 
12.81 ± 1.14 (146) 
7.95 ± 1.06 (96) 
14.63 ± 1.38 (175) 
(95) 
Education level 
  < 12 years 
  12 years 
  > 12 years 
  Missing (n) 
 
17.83 ± 0.82 (1869) 
27.30 ± 0.86 (1545) 
54.87 ± 1.26 (2886) 
(6) 
 
53.14 ± 1.73 (884) 
21.18 ± 1.35 (252) 
25.68 ± 1.61 (344) 
(2) 
 
12.76 ± 0.93 (586) 
28.42 ± 0.99 (987) 
58.82 ± 1.53 (1952) 
(4) 
 
28.14 ± 1.80 (399) 
23.85 ± 1.33 (306) 




 Missing (n) 
 
82.53 ± 0.95 (4989) 
(45) 
 
50.89 ± 2.47 (891) 
(15) 
 
86.67 ± 0.99 (3110) 
(13) 
 
75.86 ± 1.87 (988) 
(16) 
Smoking status 
  Past 
  Present 
  Never 
  Missing (n) 
 
46.57 ± 1.32 (1613) 
47.18 ± 1.44 (1351) 
6.25 ± 0.53 (197) 
(3145) 
 
44.20 ± 2.55 (338) 
45.19 ± 2.96 (236) 
10.61 ± 2.13 (60) 
(848) 
 
48.07 ± 1.43 (1061) 
45.66 ± 1.56 (795) 
6.28 ± 0.57 (120) 
(1553) 
 
34.09 ± 2.28 (214) 
62.99 ± 2.32 (320) 
2.93 ± 0.74 (17) 
(744) 
Drinking status 
  0 - 30 
  31 - 60 
  61 - 100 
  > 100 
  Missing (n) 
 
79.53 ± 0.94 (3140) 
11.69 ± 0.57 (435) 
5.53 ± 0.47 (197) 
3.24 ± 0.30 (127) 
(2407) 
 
80.07 ± 1.78 (702) 
12.21 ± 1.45 (101) 
4.76 ± 0.94 (38) 
2.96 ± 0.69 (28) 
(613) 
 
79.19 ± 1.14 (1857) 
11.98 ± 0.70 (275) 
5.71 ± 0.55 (128) 
3.13 ± 0.34 (69) 
(1200) 
 
82.08 ± 2.07 (581) 
8.77 ± 1.11 (59) 
4.66 ± 0.82 (31) 
4.48 ± 1.24 (30) 
(594) 
Daily physical  
activity level 
  1 
  2 
  3 
  4 
  Missing (n) 
 
 
24.22 ± 0.79 (1510) 
49.89 ± 0.92 (3312) 
17.80 ± 0.64 (1001) 




16.48 ± 1.20 (273) 
56.15 ± 1.42 (861) 
13.40 ± 1.00 (182) 




24.80 ± 0.93 (891) 
48.64 ± 1.01 (1753) 
18.67 ± 0.70 (635) 




25.57 ± 1.34 (346) 
54.15 ± 1.58 (698) 
14.82 ± 1.05 (184) 
5.46 ± 0.97 (65) 
(2) 
Minutes of  
household activity 
  0 
  1 - 450  
  451 - 900 
  901 - 1800 
  > 1800 
  Missing (n) 
 
 
32.33 ± 1.15 (2565) 
35.29 ± 0.80 (1970) 
15.29 ± 0.57 (823) 
10.18 ± 0.60 (549) 




51.77 ± 1.88 (780) 
28.80 ± 1.70 (394) 
9.97 ± 1.05 (148) 
5.89 ± 0.66 (89) 




27.79 ± 1.11 (1125) 
36.56 ± 0.97 (1183) 
16.66 ± 0.67 (551) 
11.20 ± 0.68 (384) 




50.12 ± 2.07 (660) 
30.99 ± 1.44 (393) 
9.59 ± 0.77 (124) 
6.15 ± 0.82 (76) 





Table 14. Prevalence of socioeconomic and lifestyle factors – males 
 
 All races/        
ethnicities 
(% ± S.E. (n)) 
Mexican  
Americans  
(% ± S.E. (n)) 
Non-Hispanic  
whites 
(% ± S.E. (n)) 
Non-Hispanic  
blacks 
(% ± S.E. (n)) 
Age 
  20-39 
  40-59 
  ≥ 60 
  Missing (n) 
 
39.28 ± 1.24 (1060) 
40.21 ± 1.00 (1028) 
20.51 ± 1.00 (1154) 
(0) 
 
62.74 ± 2.10 (315) 
28.68 ± 1.86 (219) 
8.58 ± 0.90 (246) 
(0) 
 
35.62 ± 1.36 (495) 
41.69 ± 1.11 (609) 
22.69 ± 1.18 (725) 
(0) 
 
46.25 ± 2.63 (250) 
39.16 ± 2.48 (200) 




  0 - 0.99 
  1 - 1.99 
  2 - 2.99 
  3 - 3.99 
  4 - 4.99 
  5 
  Missing (n) 
 
 
10.29 ± 0.67 (474) 
18.41 ± 1.05 (745) 
16.03 ± 1.01 (515) 
15.51 ± 0.81 (400) 
11.40 ± 0.73 (287) 




26.50 ± 2.58 (191) 
32.77 ± 2.19 (248) 
17.51 ± 1.87 (122) 
10.64 ± 1.49 (72) 
5.58 ± 1.12 (44) 




7.15 ± 0.76 (166) 
16.06 ± 1.35 (348) 
15.45 ± 1.20 (281) 
16.33 ± 1.00 (254) 
12.43 ± 0.84 (191) 




19.89 ±  2.07 (117) 
23.72 ± 1.99 (149) 
19.05 ± 1.63 (112) 
13.52 ± 1.60 (74) 
8.63 ± 1.21 (52) 
15.19 ± 1.75 (92)  
(49) 
Education level 
  < 12 years 
  12 years 
  > 12 years 
  Missing (n) 
 
17.98 ± 0.98 (989) 
27.99 ± 1.18 (797) 
54.03 ± 1.44 (1451) 
(5) 
 
52.77 ± 2.22 (470) 
24.19 ± 2.17 (143) 
23.04 ± 1.88 (166) 
(1) 
 
12.16 ± 1.14 (305) 
28.79 ± 1.39 (498) 
59.05 ± 1.85 (1022) 
(4) 
 
31.20 ± 2.59 (214) 
25.38 ± 1.85 (156) 





 Missing (n) 
 
80.84 ± 1.08 (2523) 
(23) 
 
50.31 ± 2.70 (459) 
(8) 
 
85.68 ± 1.15 (1600) 
(7) 
 
70.93 ± 2.32 (464) 
(8) 
Smoking status 
  Past 
  Present 
  Never 
  Missing (n) 
 
46.24 ± 1.45 (986) 
47.43 ± 1.51 (808) 
6.33 ± 0.73 (117) 
(1331) 
 
43.33 ± 2.82 (235) 
46.89 ± 3.30 (166) 
9.77 ± 2.49 (38) 
(341) 
 
48.49 ± 1.64 (637) 
45.16 ± 1.73 (439) 
6.36 ± 0.83 (69) 
(684) 
 
28.42 ± 2.66 (114) 
68.63 ± 2.84 (203) 
2.95 ± 0.99 (10) 
(306) 
Drinking status 
  0 - 30 
  31 - 60 
  61 - 100 
  > 100 
  Missing (n) 
 
71.36 ± 1.28 (1644) 
14.37 ± 0.76 (312) 
8.78 ± 8.74 (172) 
5.48 ± 0.50 (116) 
(998) 
 
72.23 ± 2.38 (410) 
16.50 ± 2.03 (86) 
7.00 ± 1.41 (37) 
4.27 ± 1.02 (26) 
(221) 
 
 70.95 ± 1.58 (935) 
14.30 ± 0.97 (181) 
9.29 ± 0.87 (112) 
5.47 ± 0.60 (65) 
(536) 
 
 74.09 ± 3.18(299) 
12.77 ± 1.90 (45) 
6.25 ± 1.24 (23) 
6.89 ± 1.95 (25) 
(241) 
Daily physical  
activity level 
  1 
  2 
  3 
  4 
  Missing (n) 
 
 
21.43 ± 0.93 (693) 
44.74 ± 1.28 (1550) 
19.93 ± 0.97 (591) 




12.55 ± 1.41 (115) 
47.96 ± 1.78 (394) 
16.84 ± 1.64 (125) 




22.54 ± 1.15 (429) 
43.40 ± 1.52 (832) 
20.54 ± 1.14 (359) 




20.80 ± 1.52 (149) 
51.97 ± 2.32 (324) 
 18.03 ± 1.44 (107) 
9.20 ± 1.81 (51) 
(2) 
Minutes of  
household 
activity 
  0 
  1 - 450  
  451 - 900 
  901 - 1800 
  > 1800 




28.29 ± 1.36 (1179) 
36.68 ± 0.96 (1076) 
15.58 ± 0.70 (439) 
11.37 ± 0.73 (314) 





50.25 ± 2.41 (388) 
30.70 ± 2.14 (232) 
10.13 ± 1.37 (79) 
5.75 ± 0.88 (46) 





23.44 ± 1.36 (499) 
37.46 ± 1.19 (621) 
17.02 ± 0.80 (297) 
12.71 ± 0.83 (229) 





45.37 ± 2.61 (292) 
36.07 ± 2.08 (223) 
9.54 ± 1.16 (63) 
6.28 ± 1.02 (39) 





Table 15. Prevalence of socioeconomic and lifestyle factors – females 
 
 All races/        
ethnicities 
(% ± S.E. (n)) 
Mexican  
Americans  
(% ± S.E. (n)) 
Non-Hispanic  
whites 
(% ± S.E. (n)) 
Non-Hispanic  
blacks 
(% ± S.E. (n)) 
Age 
  20-39 
  40-59 
  ≥ 60 
 
34.37 ± 1.21 (904) 
39.93 ± 0.94 (1004) 
25.70 ± 1.09 (1156) 
 
53.68 ± 2.32 (222) 
32.66 ± 1.40 (223) 
13.66 ± 1.54 (257) 
 
31.47 ± 1.31 (444) 
40.53 ± 1.12 (539) 
28.00 ± 1.31 (717) 
 
42.26 ± 1.83 (238) 
40.12 ± 1.72 (242) 
17.62 ± 1.60 (182) 
Menopausal 
  Missing (n) 
27.95 ± 1.30 (629) 
(1200) 
15.95 ± 2.30 (125) 
(300) 
30.00 ± 1.63 (395) 
(655) 




  0 - 0.99 
  1 - 1.99 
  2 - 2.99 
  3 - 3.99 
  4 - 4.99 
  5 
  Missing 
 
 
11.98 ± 0.93 (486) 
22.57 ± 0.98 (781) 
15.18 ± 0.77 (444) 
14.91 ± 0.89 (370) 
10.63 ± 0.72 (242) 




29.35 ± 3.05 (189) 
34.21 ± 2.31 (215) 
12.54 ± 1.93 (89) 
12.10 ± 1.26 (66) 
4.05 ± 0.84 (30) 




8.76 ± 0.99 (155) 
20.78 ± 1.15 (394) 
15.50 ± 0.89 (264) 
15.55 ± 1.05 (232) 
11.67 ± 0.85 (168) 




23.82 ± 2.11 (142) 
27.99 ±  2.00 (172) 
14.50 ± 1.31 (91) 
12.19 ± 1.24 (72) 
7.36 ± 1.53 (44) 
14.14 ± 1.69 (83) 
(58) 
Education level 
  < 12 years 
  12 years 
  > 12 years 
  Missing 
 
17.69 ± 0.97 (880) 
26.62 ± 0.97 (748) 
55.69 ± 1.53 (1435) 
(1) 
 
53.62 ± 2.39 (414) 
17.28 ± 1.42 (109) 
29.09 ± 2.14 (178) 
(1) 
 
13.34 ± 1.06 (281) 
28.06 ± 1.18 (489) 
58.60 ± 1.79 (930) 
(0) 
 
25.57 ± 2.16 (185) 
22.58 ±1.78 (150) 




 Missing (n) 
 
84.17 ± 1.06 (2466) 
(22) 
 
51.64 ± 3.03 (432) 
(8) 
 
87.63 ± 1.09 (1510) 
(6) 
 
79.98 ± 2.41 (524) 
(8) 
Smoking status 
  Past 
  Present 
  Never 
  Missing (n) 
 
46.97 ± 1.77 (627) 
46.87 ± 1.89 (543) 
6.16 ± 0.69 (80) 
(1814) 
 
46.37 ± 4.52 (103) 
40.92 ± 4.39 (70) 
12.71 ± 2.98 (22) 
(507) 
 
47.58 ± 1.91 (424) 
 46.24 ± 1.99 (356) 
6.18 ± 0.77 (51) 
(869) 
 
41.21 ± 3.28 (100) 
55.88 ± 3.14 (117) 
2.90 ± 1.17 (7) 
(438) 
Drinking status 
  0 - 30 
  31 - 60 
  61 - 100 
  > 100 
  Missing (n) 
 
89.06 ± 1.00 (1496) 
8.57 ± 0.90 (123) 
1.74 ± 0.41 (25) 
0.63 ± 0.24 (11) 
(1409) 
 
96.03 ± 0.95 (292) 
3.46 ± 0.91 (15) 
0.20 ± 0.20 (1) 
0.31 ± 0.22 (2) 
(392) 
 
 88.38 ± 1.17 (922) 
9.39 ± 1.03 (94) 
1.71 ±  0.45 (16) 
0.52 ± 0.27 (4) 
(664) 
 
91.02 ± 1.45 (282) 
4.30 ± 1.37 (14) 
2.89 ± 1.05 (8) 
1.78 ± 0.81 (5) 
(353) 
Daily physical  
activity level 
  1 
  2 
  3 
  4 
  Missing (n) 
 
 
26.93 ± 1.05 (817) 
54.90 ± 1.38 (1762) 
15.72 ± 0.92 (410) 




21.55 ± 1.52 (158) 
66.73 ± 1.85 (467) 
8.96 ± 1.27 (57) 




26.99 ± 1.17 (462) 
 53.71 ± 1.57 (921) 
16.87 ± 1.10 (276) 




29.56 ± 2.01 (197) 
55.98 ± 1.98 (374) 
12.13 ± 1.51 (77) 
2.33 ± 0.86 (14) 
(0) 
Minutes of  
household 
activity 
  0 
  1 - 450  
  451 - 900 
  901 - 1800 
  > 1800 




36.27 ± 1.26 (1386) 
33.93 ± 1.14 (894) 
15.01 ± 0.80 (384) 
9.02 ± 0.67 (235) 





53.73 ± 2.52 (392) 
26.35 ± 1.79 (162) 
9.75 ± 1.31 (69) 
6.08 ± 1.08 (43) 





31.99 ± 1.29 (626) 
35.70 ± 1.36 (562) 
16.30 ± 1.01 (254) 
9.74 ± 0.79 (155) 





54.09 ± 2.54 (368) 
26.75 ± 2.15 (170) 
9.63 ± 1.11 (61) 
6.03 ± 1.12 (37) 





Table 16. Prevalence of Metabolic Syndrome risk factors among U.S. adults ages 
≥ 20 years old, NHANES 1999-2006 
 
† Statistically significant difference between MA and NHB 
‡ Statistically significant difference between MA and NHW 
§ Statistically significant difference between NHW and NHB 
 
* n of total missing is for both overweight and obese. Statistically significant differences exist across racial/ethnic 
groups but it is not possible to determine across which 
** Fasting plasma glucose ≥ 110 mg/dL 
 
Abbreviations:      
WC= waist circumference    TG= triglycerides 
TC= total cholesterol    HT= hypertension 
LDL= low density lipoprotein cholesterol  FPG= fasting plasma glucose  
HDL= high density lipoprotein cholesterol 
 
 
 All races/ 
ethnicities  
(% ± S.E. (n))  
Mexican  
Americans 
(% ± S.E. (n)) 
Non-Hispanic  
whites 
(% ± S.E. (n)) 
Non-Hispanic 
blacks  
(% ± S.E. (n)) 
 
Both genders 
    
BMI 
  Overweight 
 
33.98 ± 0.88 (2219) 
 
40.59 ± 1.70 (615) 
 
34.11 ± 1.00 (1225) 
 
28.40 ± 1.34 (379) 
   
  Obese 
  Missing (n)* 
 
32.87 ± 0.77 (2071) 
(101) 
 
32.37 ± 1.37 (486) 
(17) 
 
31.26 ± 0.96 (1033) 
(66) 
 




  Missing (n) 
 
52.40 ± 0.89 (3332) 
(153) 
 





52.50 ± 1.17 (1859) 
(80) 
 




  Missing (n) 
 
26.04 ± 0.87 (1699) 
(63) 
 
16.56 ± 1.08 (338) 
(9) 
 









  Missing (n) 
 
23.29 ± 0.81(1490) 
(224) 
 
15.10 ± 1.15 (283) 
(69) 
 









  Missing (n) 
 
38.43 ± 0.92 (2480) 
(65) 
 




39.43 ± 1.09 (1429) 
(33) 
 





  Missing (n) 
 
38.35 ± 0.90 (2513) 
(73) 
 




40.64 ± 1.09 (1539) 
(35) 
 





  Missing (n) 
 
42.16 ± 0.94 (3005) 
(148) 
 













  Missing (n) 
 
37.29 ± 1.21 (2658) 
(14) 
 





37.59 ± 1.40 (1481) 
(7) 
 




  Missing (n) 
 
15.79 ± 0.65 (1239) 
(14) 
 
17.11 ± 1.44 (355) 
(2) 
 
15.72 ± 0.76 (660) 
(7) 
 




  Missing (n)  
 
9.46 ± 0.49 (774) 
(0) 
 
10.39 ± 1.21 (236) 
(0) 
 
8.99 ± 0.56 (363) 
(0) 
 







Table 17. Prevalence of Metabolic Syndrome risk factors among U.S. males ages 
≥ 20 years old, NHANES 1999-2006 
 
 All races/ 
ethnicities  
(% ± S.E. (n)) 
Mexican  
Americans 
(% ± S.E. (n)) 
Non-Hispanic 
whites                   
(% ± S.E. (n)) 
Non-Hispanic 
blacks                   
(% ± S.E. (n)) 
 
Males 
    
BMI 
  Overweight 
 
40.34 ± 1.20 (1315) 
 
46.43 ± 2.14 (367) 
 
40.67 ± 1.36 (736) 
 
32.50 ± 1.96 (212) 
   
  Obese 
  Missing (n)* 
 
30.83  ± 1.06 (939) 
(44) 
 
26.73  ± 1.92 (216) 
(4) 
 
31.22 ± 1.25 (528) 
(28) 
 




  Missing (n) 
 
43.52 ± 1.26 (1351) 
(74) 
 
32.20 ± 2.62 (290) 
(12) 
 











  Missing (n) 
 
25.65 ± 1.08 (837) 
(16) 
 
17.74 ± 1.32 (169) 
(4) 
 









  Missing (n) 
 
24.23 ± 1.03 (782) 
(135) 
 
17.27 ± 1.49 (151) 
(44) 
 









  Missing (n) 
 
36.58 ± 1.22 (1191) 
(15) 
 













  Missing (n) 
 
43.51 ± 1.22 (1419) 
(22) 
 




45.93 ± 1.43 (883) 
(4) 
 





  Missing (n) 
 
44.06 ± 1.21 (1574) 
(59) 
 












  Missing (n) 
 
44.78 ± 1.40 (1565) 
(2) 
 





46.14 ± 1.61 (919) 
(1) 
 





  Missing (n) 
 
18.70 ± 1.02 (726) 
(2) 
 
18.30 ± 1.77 (198) 
(0) 
 
19.13 ± 1.18 (412) 
(1) 
 




  Missing (n) 
 
10.47 ± 0.71 (410) 
(0) 
 
9.17 ± 1.13 (113) 
(0) 
 
10.56 ± 0.83 (213) 
(0) 
 
10.92 ± 1.11 (84) 
(0) 
† Statistically significant difference between MA and NHB 
‡ Statistically significant difference between MA and NHW 
§ Statistically significant difference between NHW and NHB 
 
* n of total missing is for both overweight and obese. Statistically significant differences exist across racial/ethnic 
groups but it is not possible to determine across which 
** Fasting plasma glucose ≥ 110 mg/dL 
 
Abbreviations:      
WC= waist circumference    TG= triglycerides 
TC= total cholesterol    HT= hypertension 
LDL= low density lipoprotein cholesterol  FPG= fasting plasma glucose  






Table 18. Prevalence of Metabolic Syndrome risk factors among U.S. females 
ages ≥ 20 years old, NHANES 1999-2006 
 
 All races/ 
ethnicities  
(% ± S.E. (n)) 
Mexican  
Americans 
(% ± S.E. (n)) 
Non-Hispanic 
whites                  
 (% ± S.E. (n)) 
Non-Hispanic 
blacks                    
(% ± S.E. (n)) 
 
Females 
    
BMI 
  Overweight 
 
27.75 ± 1.09 (904) 
 
32.96 ± 1.99 (248) 
 
27.73 ± 1.23 (489) 
 
24.99 ± 1.67 (167) 
   
Obese 
  Missing (n)* 
 
34.86 ± 1.02 (1132) 
(57) 
 
39.73 ± 2.51 (270) 
(13) 
 
31.31 ± 1.23 (505) 
(38) 
 




  Missing (n) 
 
61.04 ± 1.22 (1981) 
(79) 
 
69.18 ± 2.79 (495) 
(17) 
 











  Missing (n) 
 
26.42 ± 1.06 (862) 
(47) 
 
15.03 ± 1.32 (169) 
(5) 
 









  Missing (n) 
 
22.19 ± 1.02 (708) 
(89) 
 
12.39 ± 1.47 (132) 
(25) 
 









  Missing (n) 
 
40.25 ± 1.27 (1289) 
(50) 
 












  Missing (n) 
 
33.25 ± 1.10 (1094) 
(51) 
 




35.44 ± 1.38 (656) 
(31) 
 





  Missing (n) 
 
40.29 ± 1.18 (1431) 
(89) 
 













  Missing (n 
 
29.97 ± 1.24 (513) 
(12)  
 
33.85 ± 2.97 (299) 
(2) 
 
29.29 ± 1.47 (562) 
(6) 
 




  Missing (n) 
  
11.71 ± 0.64 (513) 
(12) 
 
15.55 ± 1.97 (157) 
(2) 
 
12.42 ± 0.80 (248) 
(6) 
 




  Missing (n) 
 
8.48 ± 0.54 (364) 
(0) 
 
11.97 ± 1.84 (123) 
(0) 
 
7.47 ± 0.59 (150) 
(0) 
 




† Statistically significant difference between MA and NHB 
‡ Statistically significant difference between MA and NHW 
§ Statistically significant difference between NHW and NHB 
 
* n of total missing is for both overweight and obese. Statistically significant differences exist across racial/ethnic 
groups but it is not possible to determine across which 
** Fasting plasma glucose ≥ 110 mg/dL 
 
Abbreviations:      
WC= waist circumference    TG= triglycerides 
TC= total cholesterol    HT= hypertension 
LDL= low density lipoprotein cholesterol  FPG= fasting plasma glucose  






Table 19. Prevalence of the Metabolic Syndrome among U.S. adults ages ≥ 20 
years old, NHANES 1999-2006, calculated using the fasting plasma glucose 
cutoff of 100 mg/dL 
 
A, B, C Uppercase = significance level is p ≤ 0.01 
a, b, c Lowercase = significance level is p ≤ 0.05 




















 All races/ 
ethnicities  
(% ± S.E. (n)) 
Mexican  
Americans 
(% ± S.E. (n)) 
Non-Hispanic  
whites  
(% ± S.E. (n)) 
Non-Hispanic  
blacks                     




    












   
(457) 
















    
    Unadjusted 
A

















    Age-adjusted 
A



















    
     Unadjusted 
B
37.49 ± 1.26  
(1324) 
B
37.50 ± 2.44  
(348) 
B
37.55 ± 1.57  
(711) 
B
37.11 ± 1.59  
(265) 
    Age-adjusted 
B




















Table 20. Prevalence of the Metabolic Syndrome among U.S. adults ages ≥ 20 
years old, NHANES 1999-2006, calculated using the fasting plasma glucose 
cutoff of 110 mg/dL 
 
A, B, C Uppercase = significance level is p ≤ 0.01 
a, b, c Lowercase = significance level is p ≤ 0.05 




















 All races/ 
ethnicities  
(% ± S.E. (n)) 
Mexican  
Americans 
(% ± S.E. (n)) 
Non-Hispanic  
whites  
(% ± S.E. (n)) 
Non-Hispanic  
blacks                     




    












   
(378) 
















    
















    Age-adjusted 
A



















    
     Unadjusted 32.61 ± 1.22  
(1154) 
b
30.79 ± 2.36  
(305) 
33.15 ± 1.53  
(633) 
B
30.18 ± 1.54  
(216) 
    Age-adjusted 
B




















Table 21. Prevalence of Cardiovascular Disease among U.S. adults ages ≥ 20 
years old, NHANES 1999-2006 
 
A, B, C Uppercase = significance level is p ≤ 0.01 
a, b, c Lowercase = significance level is p ≤ 0.05 






















 All races/ 
ethnicities 
 (% ± S.E. (n))  
Mexican  
Americans 
(% ± S.E. (n)) 
Non-Hispanic  
whites  
(% ± S.E. (n)) 
Non-Hispanic  
blacks  




    






























    
















  Age-adjusted 
A



















    
















  Age-adjusted 
B






























Economic status (PIR) 0.8847 
Education 0.4260 
Health insurance 0.2730 
Smoking status 0.0429 
Alcohol intake 0.2853 
Daily activity 0.3183 
Household activity 0.3751 
BMI 0.0726 
Waist circumference 0.0002 
Systolic blood pressure 0.0001 
Diastolic blood pressure 0.0877 








 = 0.472761 
 
Abbreviations:      
PIR= poverty income ratio 
BMI = body mass index  
TG= triglycerides     
HDL= high density lipoprotein cholesterol 
LDL= low density lipoprotein cholesterol   

































-16.38          
 
3.25        
 
-22.89         
 
-9.87         
 






      
Gender 
  Male 




















  MA 
  NHW 


























  < 12 years 
  12 years 
  > 12 years 
 
























  Past 
  Present 


























  Covered 



















Daily activity level 
  1 
  2 
  3 


































      
Age 0.02 0.01 0.01 0.04 2.62 0.0110 
Economic status (PIR) 0.01 0.08 -0.15 0.18 0.15 0.8847 
Household activity 0 0 0 0 0.89 0.3751 
Alcohol intake 0 0 -0.01 0 -1.08 0.2853 
BMI -0.09 0.05 -0.19 -0.01 -1.83 0.0726 
Waist circumference 0.09 0.02 0.05 0.14 4.03 0.0002 
Systolic blood pressure 0.04 0.01 0.02 0.05 4.09 0.0001 
Diastolic blood pressure 0.02 0.01 0 0.04 1.74 0.0877 
Fasting glucose 0.11 0.01 0.08 0.14 8.01 0 
logTG 2.07 0.22 1.62 2.51 9.29 0 
logHDL -2.64 0.47 -3.59 -1.70 -5.59 0 
logLDL -1.62 0.28 -2.19 -1.06 -5.72 0 

























   
Gender 
  Male 











  MA 
  NHW 














  < 12 years 
  12 years 














  Past 
  Present 














  Covered 










Daily activity level 
  1 
  2 
  3 



















   
Age 1.02 1.01 1.04 
Economic status (PIR) 1.01 0.86 1.19 
Household activity 1 1 1 
Alcohol intake 0.99 0.99 1 
BMI 0.91 0.82 1.01 
Waist circumference 1.09 1.05 1.14 
Systolic blood pressure 1.04 1.02 1.05 
Diastolic blood pressure 1.02 1 1.04 
Fasting glucose 1.10 1.09 1.15 
logTG 7.89 5.06 12.31 
logHDL 0.07 0.03 0.18 
logLDL 0.20 0.11 0.35 






Table 25. Prevalence of Metabolic Syndrome with newly proposed triglyceride 
cutoffs among U.S. adults ages ≥ 20 years old, NHANES 1999-2006, calculated 
using the blood glucose cutoff of 100 mg/dL 
 
A, B, C Uppercase = significance level is p ≤ 0.01 
a, b, c Lowercase = significance level is p ≤ 0.05 
* Significant differences between current and new prevalence (p < 0.05) 
** Significant differences between current and new prevalence (p < 0.01) 
 
 
 All races/ 
ethnicities  
(% ± S.E. (n))  
Mexican  
Americans 
(% ± S.E. (n)) 
Non-Hispanic 
whites                   
(% ± S.E. (n)) 
Non-Hispanic 
blacks                    




    
Current 
 unadjusted 






























     
Current  
age-adjusted 

































    
Current  
unadjusted 






























     
Current  
age-adjusted 

































    
Current  
unadjusted 
37.49 ± 1.26  
(1324) 
37.50 ± 2.44  
(348) 
37.55 ± 1.57  
(711) 




**39.52 ± 1.28 
(1392) 
**39.29 ± 2.53 
(359) 
**39.20 ± 1.56 
(737) 
**41.71 ± 1.71 
(296) 
     
Current  
age-adjusted 

































Table 26. Prevalence of Metabolic Syndrome with newly proposed triglyceride 
cutoffs among U.S. adults ages ≥ 20 years old, NHANES 1999-2006, calculated 
using the blood glucose cutoff of 110 mg/dL 
 
A, B, C Uppercase = significance level is p ≤ 0.01 
a, b, c Lowercase = significance level is p ≤ 0.05 
* Significant differences between current and new prevalence (p < 0.05) 




 All races/ 
ethnicities  
(% ± S.E. (n))  
Mexican  
Americans 
(% ± S.E. (n)) 
Non-Hispanic 
whites                   
(% ± S.E. (n)) 
Non-Hispanic 
blacks                    




    
Current 
 unadjusted 






























     
Current  
age-adjusted 
32.29 ± 0.73  
(2300) 































    
Current  
unadjusted 






























     
Current  
age-adjusted 

































    
Current  
unadjusted 
32.61 ± 1.22  
(1154) 
30.79 ± 2.36  
(305) 
33.15 ± 1.53  
(633) 




**33.09 ± 1.25 
(1184)   
**32.40 ± 2.36 
(316) 
33.15 ± 1.53  
(633) 
**33.14 ± 1.69 
(235) 
     
Current  
age-adjusted 











































TG cutoff values according to Youden Index calculation: 
MA: 137 mg/dL 
NHW: 140 mg/dL 






Figure 5. Plots of sensitivity, specificity, Youden Index, Total Accuracy, and Matthew 






Figure 6. Plots of sensitivity, specificity, Youden Index, Total Accuracy, and Matthew 
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Figure 7. Plots of sensitivity, specificity, Youden Index, Total Accuracy, and Matthew 
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HDL cutoff values according to Youden Index calculation: 
MA: 40 mg/dL 
NHW: 40 mg/dL 






Figure 9. Plots of sensitivity, specificity, Youden Index, Total Accuracy, and Matthew 






Figure 10. Plots of sensitivity, specificity, Youden Index, Total Accuracy, and 
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Figure 11. Plots of sensitivity, specificity, Youden Index, Total Accuracy, and 
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HDL cutoff values according to Youden Index calculation: 
MA: 50 mg/dL 
NHW: 50 mg/dL 






Figure 13. Plots of sensitivity, specificity, Youden Index, Total Accuracy, and 






Figure 14. Plots of sensitivity, specificity, Youden Index, Total Accuracy, and 
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Figure 15. Plots of sensitivity, specificity, Youden Index, Total Accuracy, and 
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